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Abstract 
Pulmonary tuberculosis-like disease caused by non-tuberculous mycobacteria (NTM) has 
gained attention, in part, because of its increased recognition especially in the elderly and 
immunocompetent population. This is an emerging problem of public health significance. 
With the increasing incidence of case reports and series from diverse countries and regions of 
the world, the distribution of NTM species isolated from clinical samples appear to vary 
significantly by region. However, very little is known about the contribution(s) of NTM to 
tuberculosis-like disease, and significant knowledge gaps exist regarding their geographical 
distribution, clinical and molecular epidemiology in low and middle income countries 
(LMIC) where there is a high burden of disease caused by Mycobacterium tuberculosis 
complex (MTBC). This dissertation provides a state of the art review of the current 
epidemiology of NTM carriage and disease in sub-Saharan Africa and presents results from a 
study of the epidemiology of NTM in The Gambia on pulmonary carriage and disease.   
I systematically searched electronic databases (PubMed, Embase, Popline, Ovid and Africa 
Wide Information) for English language articles on pulmonary NTM in sub-Saharan Africa 
published from Jan 1,1940 to Oct 1, 2016. The American Thoracic Society and Infectious 
Disease Society of America (ATS/IDSA) diagnostic criteria was applied to differentiate 
between colonisation of NTM and clinically relevant pulmonary NTM disease. 
Mycobacterium avium complex (MAC) species were the most frequently isolated NTM 
(15.0% - 57.8%) in colonisation while M. kansasii, was the most common (184 [69.2%] of 
266) cause of confirmed pulmonary NTM disease. A significant proportion (2,623 [29.2%] of 
8,980) of NTM isolates in the studies reviewed were not identified to species level. This and 
the absence of detailed clinical and radiological data hampered the assessment of the clinical 
relevance of all NTM isolates.  
A nationwide Tuberculosis prevalence survey provided a platform for me to investigate the 
population prevalence and molecular epidemiology of NTM in pulmonary samples in the 
general population of the Gambia. Here, I confirmed suspected NTM cultures from 
decontaminated sputa stored from the parent survey by 16S rRNA gene sequencing analysis 
and applied the ATS/IDSA diagnostic criteria to determine clinical relevance of identified 
NTM. The prevalence of NTM in pulmonary samples was 39.8% [95% Confidence Interval, 
CI: 35.8% – 44.0%). M. avium complex was by far the most commonly isolated NTM 
(71.0%), followed by M. fortuitum (9.5%) and M. nonchromogenicum (2.9%). All age groups 
were three times as likely to have NTM in their sputa as the 15-24 age group (p= 0.017), 
while urban compared to rural residents were 40 times less likely to be NTM positive (p 
=0.012).  
Collectively, these findings highlight the contribution of NTM to colonisation and the risk for 
over diagnosis of smear positive TB, given the prevalence in presumptive TB cases in The 
Gambia. I have highlighted the knowledge gap resulting from incomplete identification of 
NTM species in the sub-continent and the risk of misdiagnosis of pulmonary NTM as PTB 
when smear microscopy is the sole diagnostic modality. Additional research and surveillance 
is therefore required to investigate the full contribution of NTM to pulmonary disease, 
particularly in high risk groups and it is important to review the existing tuberculosis 
identification methods for presumptive tuberculosis suspects in The Gambia, and sub-
continent.  
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CHAPTER ONE 
1 Introduction  
1.1 Non-tuberculous mycobacteria 
Non-tuberculous mycobacteria (NTM) is a designation used for many mycobacterial species 
other than the following constituent members of Mycobacterium tuberculosis complex 
(MTBC) i.e M. tuberculosis, M. bovis, M. africanum, M. canetti, M. microti, M. pinnipedii, 
and M. caprae. Of the >150 NTM species reported in the literature, 25 species have been 
strongly associated with diseases; the remainder are environmental organisms rarely 
encountered in clinical samples [1]. Interest in NTM gained traction following the onset of 
the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) 
epidemic. However, what is known of these organisms is mostly from studies/surveillance 
conducted in western and other high-income countries and very rarely from developing 
countries [2, 3].  
NTM were identified soon after Koch’s identification of M. tuberculosis as the cause of 
active TB in 1882. While many NTM species rarely if ever, cause disease, a few are 
implicated in disease and death. They are responsible for a wide array of clinical 
manifestation ranging from pulmonary (the most frequent), to lymph node (lymphadenitis, 
most common in children) and skin/soft tissue disease. Disseminated disease tends to occur 
among immunocompromised hosts and patients with single gene defects resulting in 
Mendelian susceptibility to mycobacterial diseases (MSMD) [4, 5]. For instance, 
Mycobacterium avium complex (MAC) disease can be fatal without adequate diagnosis and 
treatment in persons with HIV/AIDS [6]. 
Worldwide, there is now increasing recognition of pulmonary NTM disease in immune 
competent persons especially the elderly as a significant public health concern [2, 7-9]. 
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However, a significant knowledge gap exists concerning the geographical distribution of 
NTM, and the prevalent species in carriage and disease in low and middle income countries 
(LMIC) where there is a high burden of active MTBC disease [2, 3, 10-13]. 
1.2 Biology of non-tuberculous mycobacteria 
NTM are aerobic, slender, non-motile microorganisms and like MTBC, have the following 
characteristics: 
(1) Are acid and alcohol fast bacilli (AAFB) i.e. give a positive reaction with acid alcohol 
fast stains. 
(2) Have a guanine plus cytosine (G+C) content of deoxyribonucleic acid (DNA) of 61-
71%. 
(3) Have a thick lipid-rich, waxy cell wall that contains long chain fatty acids (C60-C90, 
mycolic acids), which on pyrolysis, are cleaved to C22 to C26 fatty acid methyl 
esters. 
(4) Exhibit intracellular pathogenicity. 
NTM include both slow growing (require 7 days or more to form colonies on subculture) and 
rapidly growing (form colonies on subculture in less than 7 days) species. In 1959, Runyon 
classified the NTM into four groups based on their rate of growth, production of pigment and 
whether this pigment is produced in the dark or only after exposure to light (Table 1).
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 Table 1:  Runyon’s classification of non-tuberculous mycobacteria 
 Category 
 
Rate of growth Description Organism 
Runyon 1 organisms 
(Photochromogens) 
Slow growing 
 
Produce a yellow-orange 
pigment when exposed to 
light 
M. kansasii, M. marinum, M. 
asiaticum, M. simiae.  
Runyon 2 organisms 
(Scotochromogens) 
Slow growing 
 
 
Produce a yellow-orange 
pigment regardless of 
whether they are grown in 
the dark or the light 
M.gordonae , M. scrofulaceum.  
Runyon 3 organisms     
(Nonchromogens) 
Slow growing Never produce pigment 
regardless of culture 
conditions 
M. avium and M. intracellulare 
(together known as Mycobacterium 
avium complex), M. ulcerans 
Runyon 4 organisms Rapidly growing 
 
Never produce pigment, 
regardless of culture 
conditions 
M. fortuitum, M. peregrinum, M. 
abscessus, M. chelonae, M. 
thermoresistible 
 
 
Slow growth of NTM is due to impermeability of the lipid-rich waxy cell wall and the 
synthetic energy cost of the long-chain mycolic acids. The extremely hydrophobic outer 
membrane of NTM predisposes them to biofilm formation in the environment and in tissue 
rather than growth in suspension. This tendency towards biofilm formation and replication in 
it, results in their preferential aerosolisation from water, [14] and increases the NTM 
resistance to disinfectants and antibiotics [15]. For example, in the post-surgical outbreak of 
M. massiliense that occurred in Brazil between 2006 and 2007, the clone BRA100 
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responsible for the epidemic was tolerant to the 2% glutaraldehyde used to disinfect surgical 
equipment [16].Thermal resistance is considered a major driver of NTM ecology. However, 
the molecular and genetic basis of this thermal resistance is poorly understood. Schulze - 
Robbecke et al. showed that it took 346 minutes at 55°C to kill 90% of M. xenopi cells - the 
most heat resistant NTM species [17]. Therefore, it is not surprising that M. xenopi outbreaks 
are often associated with water heating systems and NTM cells are frequently isolated from 
household water pipes where temperatures approach 50°C [18].  
NTM cells are also relatively resistant to low pH exemplified by survival of very large 
numbers of M. avium complex cells in the acidic, brown-water swamps off the eastern coast 
of the United States of America (USA) [19] and survival by some MAC strains in the 
stomachs of persons living with HIV [20]. However, the majority of NTM have evolved to 
grow under conditions of moderate salinity (1 to 2% NaCl) except for M. marinum, a 
pathogen of salt-water fish in aquaria. There it grows in conditions of 3 to 4% NaCl, 
approaching the salinity of the ocean. 
NTM survive and grow even better in amoebae and protozoa unlike many other bacteria that 
are consumed for carbon and energy. As a result, they are categorized as amoebae - resisting 
microorganisms (ARMS) [21]. It is hypothesized that amoebae and protozoan grazing 
resulted in selection for, and emergence of, NTM that can survive and colonise or cause 
disease in mammalian macrophages. This is supported by findings of M. avium, M. kansasii, 
M. massiliense, M. marinum and M. fortuitum strains surviving and actively replicating in 
Acanthamoeba polyphaga, Acanthamoeba castellani and in the ciliated protozoan 
Tetrahymena pyriformis [21]. 
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For many years, the phenotypic and growth rate system of Runyon as described above was 
the only method of classifying these organisms. More recently, NTM phylogeny studies 
utilizing multigene sequencing of semi-conserved genes such as those for RNA polymerase B 
(rpoB ), heat-shock protein ( hsp-65 KD) and 16S ribosomal ribonucleic acid (16S rRNA) 
have facilitated the identification of previously unknown species and led to a more extensive 
taxonomy [22, 23] as illustrated in Figure 1. 
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Figure 1: Phylogenetic relationships among Mycobacterium genus. The scale bar 
represents amino acid changes per site. Rapid growing species are shadowed in orange, 
slow growing species are shadowed in yellow, and outgroup species are shadowed in 
green. Mycobacterium tuberculosis, M. canettii, and M. kansasii are boxed in red [24].  
. 
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1.3  Epidemiology of non-tuberculous mycobacteria 
1.3.1 Occurrence and geographical distribution 
NTM are found worldwide [2, 13] and have been isolated from a variety of environmental 
sources including raw and treated water sources, water distribution systems, household 
plumbing systems, soils and animals [25, 26]. In the most comprehensive published 
description of the global distribution of NTM , M. avium complex (M. avium and M. 
intracellulare), M. gordonae, M. chelonae, M. xenopi, M. fortuitum, M. abscessus, M. 
kansasii, and M. haemophilum were the most frequently isolated NTM as shown in Figure 2. 
The prevalence of MAC, the most common NTM, ranged from a low of 31% in South 
America to a high of 71% in Australia. However, within the MAC species, significant 
continental/regional variability was noticed. For example, almost all MAC isolates from 
Australia and South Africa were M. intracellulare whereas M. avium was dominant in 
Europe, Asia, North America and South America. The distribution of M. xenopi, M. kansasii 
and rapidly growing mycobacteria (M. fortuitum, M. abscessus, M. chelonae) was also quite 
varied [13]. In addition, some NTM have been linked with specific environmental niches e.g. 
coastal regions. For example, M. xenopi is particularly prevalent in the regions of Croatia, 
Northern Italy, Ontario, Canada and in areas bordering the English Channel [8, 27]. M. 
kansasii is most frequently isolated in South America, Eastern Europe and the metropolitan 
centres of Paris, London, Tokyo and the Johannesburg region of South Africa. Urbanisation 
and commercial mining activities are major contributors to this observed distribution of M. 
kansasii [28, 29]. 
About 10-30% of all NTM isolates worldwide are rapidly growing NTM and they are most 
prevalent in Asia where they are associated with up to 50% of cases of pulmonary NTM 
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colonisation [12, 30-32]. M. simiae, which traditionally was confined to the southern United 
States, Cuba and Israel, is now emerging globally [13]. M. malmoense, M. smegmatis, M. 
interjectum, M. scrofulaceum, M. peregrinum, M. colombiense, and M. nonchromogenicum 
are rare and geographically restricted but are sporadically isolated from Europe, Asia, sub 
Saharan Africa, Southern and Northern America [2]. However, there is a dearth of data from 
sub-Saharan Africa which is also under-represented in this ‘comprehensive’ review of NTM 
epidemiology because the global NTM collection only had samples from two laboratories in 
South Africa making up about 28.0% (5646/20182) of the entire collection [13]. 
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Figure 2: Worldwide distribution of different non-tuberculous mycobacteria from 
pulmonary samples in 2008. MAC: M. avium complex; RGM: Rapidly growing 
mycobacteria (form colonies on subculture in less than 7 days); SGM: Slow growing 
mycobacteria (require 7 days or more to form colonies on subculture) [33].  
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1.3.2 Transmission 
Disease in humans occur because the habitats occupied by NTM, including community and 
domestic drinking water distribution systems, are shared with humans. Although the modes 
of transmission of NTM remain unclear, the following mechanisms have been proposed as 
the likely routes of transmission from environmental reservoirs: 
(1) Ingestion of soil or water by children leading to cervical lymphadenitis.  
(2) Inhalation of NTM-laden aerosols by adults leading to pulmonary disease. 
(3) Aspiration into the lungs by gastric reflux of ingested NTM from the stomach, leading 
to pulmonary NTM disease.  
(4) Oral ingestion of NTM in water associated with reduction of the normal barrier 
function of the gastrointestinal tract, leading to pulmonary NTM disease in patients 
with profound immunodeficiency. For example, genotyping of isolates from some 
patients with pulmonary MAC matched them to MAC isolates obtained from their 
household water systems [18]. 
(5) Direct inoculation of NTM into skin resulting in ulcers. For example, M. marinum, a 
slow-growing mycobacterium, commonly causes a cutaneous disease otherwise 
known as swimming pool or fish tank granuloma in fish tank fanciers. However, use 
of swimming pool slides and contact with fish have all been associated with 
development of M. marinum disease, both in developed and developing countries [2]. 
Unlike its highly pathogenic relative MTBC, it is believed neither human-to-human nor 
zoonotic NTM disease occur. However, the likelihood of human-to-human spread has been 
raised by genotyping reports of identical M. abscessus ss. massiliense in an outbreak among 
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patients with cystic fibrosis (CF) seen in the same clinic [34]. Evidence in support of this is 
drawn from the extensive evaluations of the clinic that did not find any environmental source 
of the pathogen. In addition, these patients had no common environmental or other exposure 
beyond shared time within the CF centre. Therefore, research aimed at improving our 
understanding of NTM transmission should be a priority as this may provide a means of 
intervening to prevent disease in the susceptible host. 
1.3.3 Risk factors for non-tuberculous mycobacteria diseases  
Although NTM are widespread in the environment and humans are literally surrounded by 
these organisms, [35] relatively few people develop NTM disease, suggesting that disease is 
opportunistic and that some individuals have an intrinsic vulnerability. 
Secondary immunodeficiency due to HIV/AIDS is the most common reported risk factor for 
NTM diseases. In persons living with HIV, disseminated NTM disease typically occur when 
they are severely immunosuppressed i.e. CD4 + T-lymphocyte counts have fallen below 
50/μl, suggesting that specific T-cell products or activities are required for NTM resistance 
[2, 36] 
Similarly, evidence from patients with Mendelian susceptibility to mycobacterial disease, a 
primary immunosuppressive condition, highlights the importance of the Interleukin (IL) 
12/23-Interferon (IFN) gamma pathway in preventing disseminated disease with NTM [4]. 
Abnormal α1- antitrypsin (AAT) phenotypes have also been identified as risk factors for 
NTM idisease [37]. In addition, immunosuppressive chemotherapy for cancer and other 
autoimmune and rheumatoid conditions are the most common risk factors for M. avium, M. 
intracellurare, M. abscessus and M. kansasii diseases.  
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Lung damage resulting from previous TB disease, chronic obstructive pulmonary disease 
(COPD), occupational exposures to dusts (e.g., mining), CF, bronchiectasis, pneumoconiosis, 
pulmonary alveolar proteinosis, all of which reduce pathogen clearance in the lungs, increase 
susceptibility to NTM colonization and disease [2, 7, 38-40].  
In the United States of America and Europe, pulmonary NTM disease has also been reported 
frequently in tall, slender, post-menopausal women without recognized predisposing factors 
[2, 7, 38]. This has led investigators to speculate that abnormal expression of sex hormones 
may play an important role in their susceptibility. For unknown reasons, women are more 
likely to have pulmonary NTM disease than men and pulmonary NTM disease prevalence 
appears to rise with increasing age (Figure 3) [41, 42]. The immunosenescence associated 
with advancing age is a well-described phenomenon associated with an increased 
susceptibility to disease, including mycobacteria. 
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Figure 3: Average annual prevalence of pulmonary non-tuberculous mycobacteria 
disease by age at four intergrated health care delivery systems, (Group Health and 
Kaiser Permanente Southern California combined), 2004-2006 [42]. 
 
1.4 Human non-tuberculous mycobacteria colonisation and disease 
1.4.1 Non-tuberculous mycobacteria disease 
Given the pervasive nature of NTM in the environment, they are very commonly seen as 
commensals (temporary or permanent) of the human respiratory or digestive tract [13, 25, 37, 
43, 44]. As a consequence of this, presence of antibodies to a common mycobacterial antigen, 
lipoarabinomannin (LAM), in settings where MTBC is uncommon, is predominantly 
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attributed to NTM colonisation [45, 46]. While colonisation rates of 1-15/100,000 persons 
have been reported in North America and Europe, [2, 5] the prevalence of NTM carriage is 
largely unknown for most countries in sub-Saharan Africa. There is value in investigating 
their prevalence in carriage and disease in this region of the world where MTBC is more 
common and NTM colonisation may have implications for diagnosis of MTBC, especially in 
pulmonary samples. In addition, it is possible that cases of NTM disease especially 
pulmonary manifestations may be masked by or missed because of the focus on MTBC as 
part of TB control efforts. 
Skin test studies in adults using NTM sensitins (antigens) indicate that a substantial 
proportion have had prior clonisation with NTM [46, 47]. For instance, skin test studies with 
an M. intracellulare purified protein derivative (PPD-B) conducted among Navy recruits in 
the United States of America in the 1960s showed reactions of greater than four millilitres 
induration were more common in the south-eastern than northern United States, suggesting 
higher background rates of NTM colonisation in these areas [47]. Reactions to skin tests 
derived from NTM are not sufficiently species-specific to indicate which NTM might have 
been responsible for these asymptomatic colonisation, and it is possible that cross-reactivity 
with MTBC disease contributed to some of these reactions. However, because MAC 
organisms are the most common cause of NTM disease in the United States, it is likely that 
MAC was also the most common cause of colonisation. Compared to MTBC, NTM carriage 
is not like latent M. tuberculosis infection, as it is not associated with any potential for 
progression to, or reactivation of, active disease. 
Differences in NTM species distribution have been proposed as a mechanism to explain the 
variable geographical efficacy of (0-80%)  Bacille Calmette–Guerin (BCG) vaccination [48, 
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49] while other studies have shown that adaptive immunity developed by exposure to NTM 
in some regions of the world may provide cross-protection against TB and leprosy diseases 
[50]. Studies on subjects in the United Kingdom and Malawi found population differences in 
immune responses following BCG vaccination that were attributed to differential 
sensitisation due to exposure to NTM [51]. [49, 50]. 
1.4.2 Non-tuberculous mycobacteria disease 
Like MTBC, NTM have the potential to infect and cause disease in any organ or part of the 
body given the opportunity, especially in the immunocompromised host. The spectrum of 
disease ranges from self-limited furunculosis to life-threatening disseminated diseases. 
1.4.2.1 Pulmonary non-tuberculous mycobacteria disease and recent trends 
The most common clinical manifestation of NTM is pulmonary disease [7, 52-56] and this 
makes up about 90% of all NTM diseases. Although there are more than 150 NTM species, 
pulmonary disease is most commonly due to MAC followed by M. abscessus/M. chelonae as 
shown in Figure 4. More recently, unusual NTM species associated with lung disease such as 
M. arupense, M. cosmeticum, M. iranicum, M. kubicae, M. monascence, M. novocatrense, M.
 tusciae and M. yongonense [57], M. szulgai [58], M. porcinum [59] and M. massiliense [60] 
have been described in the United States, Asia and Europe. 
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Figure 4: NTM species distribution in confirmed pulmonary non-tuberculous 
mycobacterial patients, Oregon 2005 to 2006 [61]. 
 
Over the last three decades, the incidence of NTM isolated from pulmonary samples and 
pulmonary NTM disease has shown an increasing trend worldwide. In the United States, the 
prevalence of pulmonary NTM disease more than doubled between 1997 and 2007 while TB 
disease incidence remained stable or declined [41]. Similarly, Koh et al. reported increasing 
recovery of NTM from respiratory specimens in a tertiary referral hospital in South Korea, as 
shown in Figure 5 [62]. 
87%
6%, 
3%
4%
M. avium complex M. abscessus/M.chelonae
Not MAC/not speciated Other
Introduction 
 
Page | 32 
      
CHAPTER ONE 
 
 
Figure 5: Increasing recovery of non-tuberculous mycobacteria from respiratory 
specimens over a 10-year period in a tertiary referral hospital in South Korea [63].  
 
Other investigators in Croatia also found MTBC isolates from pulmonary samples declined 
two-fold while the number of NTM isolates almost doubled in the same period (Figure 6) 
[27].  
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Figure 6: Total number of Mycobacterium spp., M. tuberculosis and pulmonary NTM 
isolates submitted to the Croatian national reference laboratory during the study period 
2006-2010 [27].  
 
More recently, Yoon and colleagues showed that the age-adjusted prevalence of pulmonary 
NTM colonisation in women was higher than that in men, and the differences increased by 
year; the prevalence rates for men and women between 2009 and 2016 were 8.6 and 25.3, and 
10.3 and 46.8, respectively. However, the prevalence and incidence of TB per 100,000 
population decreased between 2009 and 2016 (106.5 and 74.4 for prevalence; 81.2 and 61.8 
for incidence) as illustrated in Figure 7 [64]. 
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Figure 7: Prevalence and incidence of tuberculosis, and prevalence of nontuberuclous 
mycobacterial diseases per 100,000 population in Korea (2009-2016) [64]. 
 
This relative increase in NTM isolation and pulmonary NTM disease has occurred while TB 
cases declined leading to speculation that waning cross-protective mycobacterial immunity 
from TB disease might have contributed to an increase in NTM disease [2, 65]. Although 
there might be a true increase in disease prevalence, alternative explanations for this 
observation include declining MTBC disease, improved laboratory techniques [1, 2], greater 
disease awareness [7], pseudo infections from hospital contamination (during collection of 
specimen), and /or laboratory contaminations (during specimen processing) [7, 66, 67]. 
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1.4.2.2 Challenges with describing the global epidemiology of pulmonary non-
tuberculous mycobacterial disease 
Most of the available data on NTM lung disease prevalence is reported from United States, 
middle-income Asian countries, and Europe [2, 7, 68]. There are several obstacles in the way 
of obtaining detailed pulmonary NTM disease epidemiology for other parts of the world. 
First, as NTM diseases are not notifiable, there are no formal surveillance systems in place to 
capture data and case data are not usually reported to Public Health Authorities in many 
regions of the world, especially in sub-Saharan Africa. Secondly, the overlapping clinical 
manifestations with MTBC disease in high TB burden settings make the specific diagnosis of 
NTM disease difficult. For example, slow growing NTM such as M. kansasii and M. szulgai 
cause pulmonary tuberculous-like disease making the differential diagnosis of pulmonary 
NTM and TB disease challenging [1, 58]. Finally, NTM can colonise the respiratory tract, 
finding NTM in respiratory secretions does not necessarily confirm clinical disease [2, 5, 69]. 
In 1997, the American Thoracic Society and Infectious Diseases Society of America 
(ATS/IDSA) developed a rigorous case definition for differentiation of casual NTM isolation 
from true pulmonary NTM disease. These guidelines were revised in 2007 to include more 
lenient diagnostic criteria and require clinical, radiological and microbiological evidence for 
diagnosis (see Table 2) [2]. Unfortunately, in most epidemiological studies, the difficulty of 
obtaining complete radiographic and clinical data has prevented accurate assessment of true 
pulmonary NTM disease prevalence [7, 37]
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Table 2: Summary of the American Thoracic Society/Infectious Disease Society of 
America Diagnostic criteria for pulmonary non-tuberculous mycobacterial disease 
Clinical  
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-
resolution computed tomographic scan that shows multifocal bronchiectasis with 
multiple small nodules. 
And 
2. Appropriate exclusion of other diagnoses. 
Microbiologic 
1. Positive culture results from at least two separate expectorated sputum samples (If the 
results from the initial sputum samples are non-diagnostic, consider repeat sputum acid-
fast bacillus (AFB) smears and cultures). 
OR 
2. Positive culture results from at least one bronchial wash or lavage. 
OR 
3. Transbronchial or other lung biopsy with mycobacterial histopathological features 
(granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing 
mycobacterial histopathological features (granulomatous inflammation or AFB) and one 
or more sputum or bronchial washings that are culture positive for NTM. 
4. Expert consultation should be obtained when NTM are recovered that are either 
infrequently encountered or that usually represent environmental contamination 
5. Patients who are suspected of having NTM lung disease but who do not meet the 
diagnostic criteria should be followed until the diagnosis is firmly established or 
excluded.  
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1.5 Non-tuberculous mycobacteria extra pulmonary disease 
Approximately 10% of all NTM disease manifest as extra pulmonary disease [55, 70]. The 
portals of entry are the respiratory tract, gastrointestinal tract, or direct inoculation through 
trauma or invasive procedures. Common extra pulmonary disease manifestations include 
cervical lymphadenitis, disseminated disease, skin, and soft tissue and bone diseases. 
Keratitis, catheter-related bloodstream diseases, septic arthritis and central nervous system 
diseases also occur but are uncommon. 
The rapid growers, including M. chelonae, M. abscessus, and M. fortuitum are predominant 
causative agents [70]. The incidence and prevalence of extra pulmonary disease is unknown 
worldwide. Where outbreaks have been reported, these are mainly due to inadequate 
disinfection of surgical equipment or contamination of injected solutions or medications [2, 
16]. 
1.6 Treatment of non-tuberculous mycobacterial diseases 
NTM are relatively resistant to antimicrobial compounds owing to their impermeable cell 
wall and broad repertoire of efflux pumps characteristic of mycobacteria [71]. Nonetheless, 
the availability of newer macrolides/azilides have drastically improved this situation and are 
now the cornerstones of therapy for most NTM diseases [2]. Azithromycin and 
clarithromycin have excellent in vitro activity against MAC [72] and are able to achieve 
penetration into phagocytes and tissues [73]. These drugs have therefore become central to 
the treatment of MAC lung diseases and extrapulmonary diseases. For M. kansasii disease, 
prolonged triple drug therapy including isoniazid (INH), rifampin, and ethambutol is 
recommended. Patients are treated until sputum culture negative on therapy for at least 12 
Introduction 
 
Page | 38 
      
CHAPTER ONE 
months. Recently, macrolides such as clarithromycin and the fourth-generation 
fluoroquinolone, moxifloxacin, have been shown to have in vitro activity against this 
organism and may soon become an alternative to INH [74]. 
Diseases caused by rapidly growing mycobacteria, especially M. abscessus, are notoriously 
difficult to treat successfully with drug therapy alone. Chemotherapy in conjunction with 
surgical resection is often needed in those who can tolerate it and IFN gamma has been used 
in some trials [70].  
Studies of phylogeny, drug susceptibility, and clinical significance of mycobacteria have led 
investigators to hypothesize that drug susceptibility in mycobacteria is acquired and reflects 
the level of competition in, and adaptation to, the human (environmental) niche of the 
mycobacteria. This is supported by the fact that the most virulent NTM (M. marinum, M. 
ulcerans, M. kansasii, M. szulgai, and M. malmoense) are most adapted to humans and 
phylogenetically closer to MTBC compared to other NTM. In addition, they possess the 
ESX-1 system (a type VII secretion system responsible for the secretion of Early Secreted 
Antigenic Target 6 (ESAT-6) and Culture Filtrate Protein (CFP) 10 proteins, which are 
crucial for M. tuberculosis complex virulence), are characterized by high levels of natural 
drug susceptibility and cause disease that are most treatable [2, 22, 75, 76]. In contrast, NTM 
that inhabit the more competitive environmental niches such as M. gordonae, M. fortuitum, 
M. chelonae, and M. simiae are phylogenetically distant to MTBC, and have a low clinical 
significance because they are the least adapted to humans. When found in disease, curative 
therapy is difficult because they are most tolerant to antibiotics derived from microbes with 
which they share their habitat (Figure 8).  
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Figure 8: Relationships between virulence, treatment outcome and drug susceptibility 
visualized. Note: Clinical relevance and virulence, as well as treatment outcome herein 
are based on pulmonary disease [75].  
  
1.7 Laboratory diagnosis of pulmonary non-tuberculous 
mycobacteria disease 
1.7.1 Smear microscopy and sample decontamination  
NTM are acid and alcohol fast bacilli (AAFB) and can be detected by the classical Ziehl-
Neelsen (ZN) and fluorochome staining techniques just like for MTBC [77]. As with MTBC, 
smear microscopy has poor sensitivity for diagnosing NTM diseases when the bacterial load 
is less than 10,000 organisms/ml in sputum sample Ref. The sensitivity of microscopy has 
however, increased considerably with improved techniques and standardization of sputum 
preparation. These include: 
(1) Liquefaction with N-acetyl-L-cysteine (NALC) and 2% sodium hydroxide (NaOH) 
(2) Concentration of the sputum by centrifugation. 
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(3) Promotion of the use of auramine-rhodamine with the fluorochrome method instead 
of the classic acid-fast stains of ZN and Kinyoun, which use carbol-fuchsin [1, 2]. 
Specimens from non-sterile sites, such as sputum, require decontamination to avoid 
overgrowth by fast growing bacteria or fungi. Decontamination with final concentrations of 
1% NaOH is most commonly used. An increase of NaOH concentrations from 1% to 1.25% 
has been shown to lower contamination rates but also leads to a 10% decrease in detection of 
NTM [78]. Buijtels et al. demonstrated the utility of sulphuric acid (final concentrations of 
3%) in improving detection rates of NTM compared with 1% NALC-NaOH, by liquid 
culture, without an increase in contamination rates [79]. 
1.7.2 Culture conditions and media 
 Liquid and solid media cultures are recommended for recovery and detection of NTM [2]. 
As with MTBC, liquid media culture systems such as the Mycobacteria Growth Indicator 
Tube (MGIT) methods in general are more sensitive than solid media such as Lowenstein-
Jensen, Ogawa, and Middle brook 7H10/7H11 [80-82]. In addition, these media offer the 
advantage of more rapid growth, thus significantly reducing delays to diagnosis and 
treatment. However, liquid culture media are more susceptible to bacterial overgrowth and 
contamination. Solid media cultures allow for visualization of bacterial colony characteristics 
and morphology, and serve as a backup when liquid cultures become contaminated [83]. 
Typical of environmental organisms, NTM are versatile in their metabolic needs. Yet, for a 
small number of species, M. genavense and M. haemophilium for example, enrichment of 
culture media is needed to facilitate growth. In the case of M. tilburgii, attempts to isolate it 
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in culture have not been successful despite its presence in large numbers in clinical samples 
[84].  
The optimal temperature for NTM cultures is between 25°C and 37°C. The culture conditions 
for NTM are shown in Table 3.  
Table 3: Culture conditions for primary isolation of non-tuberculous mycobacteria 
species 
NTM species Optimal growth 
temperatures 
Special requirements for 
growth 
M. avium complex  
M. kansasii, M. malmoense 
M.abscessus, M. chelonae  
M. fortuitum, M. gastri 
M.gordonae  
 
 
32°C to 42°C 
 
 
Not applicable (N/A) 
 
M. genavense 37°C Human blood, charcoal, 
casein, and yeast extracts, 
acidified to pH 6, 
mycobactin J 
M. conspicuum 22°C to 30°C N/A 
M. haemophilum 28°C to 32°C Iron-containing compounds 
i.e. ferric ammonium citrate, 
hemin, or hemoglobin 
M. marinum 25°C to 32°C N/A 
M. ulcerans 30°C N/A 
M. lentiflavum 22°C to 37°C N/A 
M. thermoresistible 37°C to 52°C N/A 
M. smegmatis 
M. xenopi 
37°C to 45°C 
 
N/A 
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1.7.3 Laboratory Identification of non-tuberculous mycobacteria  
Species-level identification of the NTM is becoming increasingly clinically important 
because of differences in antimicrobial susceptibility that underpin treatment options. NTM 
species differ in their ability to cause human pulmonary disease and the clinical relevance of 
NTM species have geographic variations [37, 85].  
Some other organisms belonging to the genus Nocardia/Rhodococcus have the same acid and 
alcohol fast appearance as NTM and MTBC on microscopy. Pulmonary nocardiosis is often 
misdiagnosed and treated as TB, sometimes with fatal consequences. Therefore, accurate 
identification of NTM by molecular techniques and utility of in vitro drug susceptibility 
testing for different NTM species are critical for accuracy and for effective treatment for 
pulmonary NTM diseases [2, 13, 28, 86]. 
The methods for identification of NTM in clinical laboratories have evolved over the past two 
decades from culture-based, phenotypic and biochemical identification to molecular 
techniques. These molecular diagnostic approaches are less cumbersome than conventional 
microbiological techniques with reduced turnaround time and significantly increased 
sensitivity, higher discriminative power and reproducibility [1, 22, 87]. 
Among molecular methods,  two approaches are commonly used. The first are line probe 
assays which are easy to perform and allow a reasonable level of discrimination and 
identification of the most frequently encountered species such as MAC, M. kansasii, M. 
abscessus and M. gordonae. Second is partial gene sequencing which allows a higher level of 
discrimination, often up to subspecies level, but is only feasible for laboratories with access 
to sequencing facilities. A well documented example is the 16S rRNA gene sequencing 
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technique. The 16S rRNA gene is the first and the best established technique for bacterial 
typing and was widely used before the other molecular techniques. It is ~1,500 nucleotide-
sequence encoded by the 16S ribosomal deoxyribonucleic acid (rDNA). This gene is present 
in all bacteria, containing highly conserved regions flanked by hyper variable regions making 
it an important target for bacterial identification [88]. The bacterial 16S rRNA gene contains 
nine hypervariable regions (V1-V9) ranging from about 30-100 base pairs long. The degree 
of conservation varies widely between hypervariable regions, with more conserved regions 
correlating to higher-level taxonomy and less conserved regions to lower levels, such as 
genus and species. Tortoli et al. have shown that the most interesting nucleotide for 
mycobacteria 16S rRNA gene investigations are those shared by all the members of the genus 
mycobacteria and also the hypervariable regions characterised by species specific variability 
[22]. The 16S rRNA -based genetic investigation of mycobacterial phylogeny and taxonomy 
focusses on two hypervariable sequences, known as region A (V3) and B (V5), that 
correspond to the Escherichia coli positions around 130 to 210 and 430 to 500 respectively  
(Figure 9)The 16S rRNA gene sequencing analysis was the method of choice for 
identification of NTM in this study.    
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Figure 9: Diagramatic representation of 16S rRNA gene highlighting region A(V3) and 
B(V5) for 16S rRNA-based genetic investigations of mycobacteria phylogeny and 
taxonomy. Regions A and B correspond to Escherichia coli positions 130 to 210 and 430 
to 500 respectively. Figures (1, 192 etc.) represent base pairs.  
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Recently, the matrix assisted laser desorption/ionization–time of flight mass spectrometry 
(MALDI-TOF MS) has been developed for NTM species identification[89]. This is  
an ionization technique that uses a laser energy absorbing matrix to create ions from 
large molecules with minimal fragmentation. It has been applied to the analysis 
of biomolecules and large organic molecules which tend to be fragile and fragment when 
ionized by more conventional ionization methods. MALDI-TOF mass spectrometry has 
revolutionized speed and precision of microbial identification for clinical isolates 
outperforming conventional methods. Recent studies on the utility of the MALDI-TOF 
technique for NTM identification showed that for rare NTM species, identification is 
sometimes not possible, but in most cases, the results of identification by the MALDI-TOF 
MS were concordant with the results obtained from conventional real time PCR and DNA 
hybridization methods.[89, 90] However, the optimal method for protein extraction from 
mycobacteria and the true discriminatory power of this method are yet to be established. 
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2 Rationale for Thesis  
Data on the contribution of NTM to pulmonary disease in sub-Saharan Africa is uncertain. As 
highlighted in chapter 1, sub-Saharan Africa was poorly represented in the ‘global’ NTM 
collection that led to a description of the global epidemiology of NTM in colonisation and 
disease [13]. The scarcity of data on the contribution of NTM to pulmonary mycobacterial 
infections in sub-Saharan Africa is most likely due to the following reasons: 
(1) Poor awareness among treating physicians and microbiologists on the clinical 
relevance of NTM.  
(2) Lack of laboratory infrastructure for culture and identification of mycobacterial 
isolates. 
(3) The high burden of TB and HIV in this region of the world attracts the bulk of the 
attention of the health care system. Therefore, the fiscal inputs required for diagnosis 
and treatment NTM disease are lacking.  
(4) Misdiagnosis - since sputum smear microscopy is the mainstay of TB diagnosis in 
most high burden TB settings, the risk of acid-fast NTM in pulmonary samples, 
especially in previously treated patients with lung damage, poses a diagnostic 
challenge.  
Given the paucity of data on NTM and the little understanding of the epidemiology of 
pulmonary NTM in disease and colonisation in the sub-Saharan Africa, I  conducted a 
comprehensive, systematic review of pulmonary NTM colonisation and disease in the region, 
and investigated the epidemiology and population biology of NTM found in pulmonary 
samples in a nationwide survey in The Gambia. 
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2.1 Study hypothesis 
Non-tuberculous mycobacteria are prevalent in sputum samples of TB suspects in sub-
Saharan Africa and can cause pulmonary TB-like disease 
2.2 Aims of study  
 To consolidate existing data on pulmonary NTM colonisation and disease (according 
to the ATS/IDSA criteria) in sub-Saharan Africa, review the existing gaps in our 
knowledge of pulmonary NTM and identify future research priorities. 
 To estimate the prevalence and predictors of NTM colonisation and disease in 
pulmonary samples of a representative subset of the Gambia population 
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3 Non-tuberculous Mycobacteria Isolated from Pulmonary 
Samples in sub-Saharan Africa – A Systematic Review of the 
Literature. 
 
Catherine Okoi, Suzanne T. Anderson, Martin Antonio, Sarah N. Mulwa, Florian Gehre, 
Ifedayo M.O. Adetifa 
(Submitted to Scientific Reports 7th February 2017; Revised manuscript re-submitted 24th 
June 2017 ) 
3.1 Abstract 
Background  
Pulmonary NTM disease epidemiology in sub-Saharan Africa is not as well described as for 
pulmonary tuberculosis. Earlier reviews of global pulmonary NTM epidemiology only 
included subjet-level data from one sub-Saharan African country. With the increasing 
incidence of case reports and series from diverse countries and regions of the world, the 
distribution of NTM species isolated from pulmonary samples appear to vary significantly by 
region. However, very little is known about the contribution(s) of NTM to tuberculosis-like 
disease, and significant knowledge gaps exist regarding their geographical distribution, 
clinical and molecular epidemiology in low and middle income countries where there is a 
high burden of disease caused by MTBC. 
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Methods  
We systematically reviewed the literature and searched electronic data bases (PubMed, 
Embase, Popline, OVID and Africa Wide Information) for articles on prevalence and clinical 
relevance of NTM detected in pulmonary samples in sub-Saharan Africa. We applied the 
American Thoracic Society/Infectious Disease Society of America criteria to differentiate 
between colonisation and disease.   
Findings 
Only 37 articles from 373 citations met our inclusion criteria. The prevalence of pulmonary 
NTM colonisation was 7.5% (95% CI: 7.2% - 7.8%), and 75.0% (2325 of 3096) occurred in 
males, 16.5% (512 of 3096) in those previously treated for tuberculosis and Mycobacterium 
avium complex predominated (27.7% [95% CI: 27.2 – 28.9%]). In seven eligible studies, 
27.9% (266 of 952) of participants had pulmonary NTM disease and M. kansasii with a 
prevalence of 69.2% [95% CI: 63.2 – 74.7%] was the most common cause of pulmonary 
NTM disease. NTM species were unidentifiable in 29.2%  [2,623 of 8,980] of isolates. 
Interpretation /Significance 
In conclusion, pulmonary NTM disease is a neglected and emerging public health disease in 
sub-Sharan Africa that requires enhanced surveillance to fully quantify the diversity of and 
contribution of NTM to pulmonary disease and to reduce the risk of misdiagnosis of 
tuberculosis.  
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3.2 Introduction 
The epidemiology of pulmonary disease caused by Mycobacterium tuberculosis complex 
(MTBC) - M. tuberculosis, M. bovis, M. africanum, M. canetti, M. microti, M. pinnipedii and 
M. caprae - is better known than for NTM [7]. NTM is a designation used for a large number 
of potentially pathogenic and non-pathogenic environmental mycobacterial species other than 
MTBC and Mycobacterium leprae.  
Worldwide, pulmonary disease caused by NTM are gaining increased attention, in part, 
because of increasing recognition and isolation in clinical settings and there are some better 
known NTM pathogens like M. avium subsp paratuberculosis and M. marinum 
[55, 56]. Although NTM were identified soon after Koch’s identification of M. tuberculosis 
as a cause of active tuberculosis in 1882, it was not until the 1950s that NTM were 
recognized to cause human pulmonary disease. Given their ubiquitous presence in the 
environment, it is important to distinguish colonisation from active disease following 
isolation of NTM from pulmonary samples. In response to this challenge, the ATS/IDSA 
introduced stringent diagnostic criteria with clinical, radiological and microbiological 
components for diagnosis of pulmonary NTM disease [2].  
The clinical and molecular epidemiology of prevalent NTM in low and middle-income 
countries also endemic for pulmonary tuberculosis is less known because pulmonary and 
other disease manifestations caused by NTM pose a diagnostic challenge to microbiologists 
and clinicians [1, 2]. In contrast to pulmonary tuberculosis, it is not possible to readily 
identify pulmonary NTM disease with the usual combination of basic mycobacteriology, 
clinical history, radiologic imaging and the tuberculin skin test, where applicable. The culture 
and molecular biology identification techniques required for NTM diagnosis are not cost 
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effective for routine clinical practice in resource-poor health systems where priority is 
currently given to expanding access to diagnosis and treatment for pulmonary 
tuberculosis [10, 53]. Distribution of NTM species isolated from pulmonary samples differs 
significantly by geographic region. However, most of these data are from the developed 
world and sub-Saharan Africa is under represented [13, 33]. Although there are now 
emerging NTM disease data from Asia and parts of Africa, significant knowledge gaps still 
exist especially in sub-Saharan Africa where nine of the world’s 22 high burden tuberculosis 
countries are found  
[11-13]. Therefore, fears that inconclusive diagnosis based on smear microscopy or clinical 
symptoms and/or radiological findings could lead to misdiagnosis of pulmonary tuberculosis 
and/or inappropriate management of pulmonary NTM cases are valid. The objectives of this 
review were to consolidate existing data on pulmonary NTM in sub-Saharan Africa, review 
the existing gaps in our knowledge of pulmonary NTM and identify future research priorities. 
 
3.3 Methods 
3.3.1 Literature Search and Selection Criteria  
This review was conducted in accordance with PRISMA guidelines [91]. The overall aim of 
this review was to determine the prevalence of NTM in apparently healthy and sick persons 
in sub-Saharan Africa. We defined sub-Saharan Africa as all of Africa except Northern 
Africa.   
We searched PubMed, EMBASE, POPLINE, OVID and Africa Wide Information electronic 
databases for publications about pulmonary NTM in sub-Saharan Africa published from 
January 1, 1940 to October 1, 2016 using the following search terms and strategy: 
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(((((("nontuberculous mycobacteria"[MeSH Terms] AND "africa south of the sahara"[MeSH 
Terms]) OR "mycobacterium infections, nontuberculous"[MeSH Terms]) AND "africa south 
of the sahara"[MeSH Terms]) OR "mycobacterium infections, nontuberculous"[MeSH 
Terms]) AND "africa south of the sahara"[MeSH Terms]) OR (("lung"[MeSH Terms] OR 
"lung"[All Fields] OR "pulmonary"[All Fields]) AND "nontuberculous mycobacteria"[MeSH 
Terms])) AND "africa south of the sahara"[MeSH Terms] AND (("1940/01/01"[PDAT]: 
"2016/10/01"[PDAT]) AND "humans"[MeSH Terms]).  
3.3.2 Selection process and data abstraction 
We found 373 citations from our database searches (see Figure 10). The titles and abstracts of 
all the articles were screened and full-text copies of those deemed relevant obtained. In 
addition, the reference sections of all the retrieved articles were screened to identify other 
eligible citations. Only articles reporting on pulmonary samples were included. For all 
relevant articles, we extracted the following data using a data extraction sheet: research 
setting, study period, population tested and numbers, NTM species isolated, method for NTM 
identification, prevalence of pulmonary NTM isolation/disease, HIV co-infection rate and 
risk factor(s) for NTM acquisition.   
3.3.3 Data analysis 
In estimating country-level and overall prevalence of NTM in sub-Saharan Africa, a pooled 
estimate was computed based on a simple meta-analysis of the reported prevalences. Each 
study was weighted according to its sample size and the exact binomial used to derive the 
95% confidence intervals (95% CI). We checked all retrieved articles for application of the 
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ATS/IDSA diagnostic criteria (Table 4) for clinically relevant pulmonary NTM and recorded 
the proportion of patients meeting these criteria and NTM species responsible.  
All extracted data were stored in Microsoft® Excel® (Microsoft Corporation, Redmond, 
Washington, United States) and analysis carried out in STATA™ version 12.1 (College 
Station, Texas, United States)
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PubMed 
345 citations 
identified 
EMBASE 
4 citations 
identified 
POPLINE 
16 citations 
identified 
Africa-wide 
Information 
2 citations 
identified 
6 citations 
identified 
through list of 
relevant 
articles 
 
373 citations identified from 
searches 
 
Articles excluded based on titles and 
abstracts (332) 
 
41 articles relevant  
for review 
 
 
Insufficient data 
 (4) 
 
37 articles included  
in review 
 
Figure 10: Flow chat on literature selection criteria and article search 
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3.4 Results  
3.4.1 Distribution of included studies  
There were only 37 relevant articles on the epidemiology of pulmonary NTM in sub-Saharan 
Africa as shown in Table 4. These were from studies in western (Nigeria, Mali and Ghana), 
southern (Zambia and South Africa [RSA]) and eastern (Kenya, Uganda, Tanzania and 
Ethiopia) Africa [9, 10, 13, 29, 38, 53, 69, 92-121]. Eleven articles were from Nigeria [53, 
92-101] one from Mali [102] one from Ghana [103] six from Zambia [10, 79, 104-107] two 
from Kenya [108, 109] two from Uganda [110, 111] three from Tanzania [9, 112, 113] three 
from Ethiopia [114-116] and eight from South Africa [13, 29, 38, 117-121]. Where methods 
of identification were reported, molecular techniques (n= 26) were the most frequently used 
to identify NTM species, followed by conventional biochemical testing identification tools 
(n= 9) and immunochromatographic assays (n=2). The molecular diagnostic methods used 
were Restriction Fragment Polymerase Chain Reaction (RFPCR) of the 65KD hsp gene, 
Genotype CM/AS assay (Hain Life science, Nehren, Germany), and 16S rRNA gene 
sequencing analysis in one, eleven and fourteen studies respectively. Identification methods 
also varied over time and a dramatic rise in the use of molecular methods was observed in the 
period 2000-2016. Biochemical and phenotypic tools were the only methods used for NTM 
identification before 2000. Despite this transition in identification methods used over time, 
there was no major change in diversity of NTM species isolated in the period before and after 
the year 2000 as shown in Table 5. 
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Table 4: Overview of studies on pulmonary non-tuberculous mycobacteria in sub Saharan Africa 
Country Study 
period 
Reference Age in 
years 
Sample size Sputum cultures Most isolated 
NTM 
Method of 
NTM 
identification 
Overall 
prevalence 
of NTM 
isolation (%) 
Pulmonary 
NTM patients 
with HIV 
coinfection (%)  
 
ATS/IDSA 
applied/number
s meeting 
criteria 
Risk factors 
for 
pulmonary 
NTM MTBC NTM 
Ethiopia 2010 Mathewos et al. 
(2015) [115]  
NA 263 
presumptive 
TB cases 
110 7 NTM not classified Immunochro-
matography 
assay (Capilia 
TAUNS 
method) 
2.7 NA No NA 
 
Ethiopia 2011 Workalemahu et 
al.  (2015) [116]  
1-15 121            
presumptive 
TB cases 
15 10 M. fortuitum              
M. 
parascrofulaceum 
M. triviale 
Molecular  
(Sequencing of 
16S rRNA  
gene) 
 
8.3 NA NA NA 
Ethiopia 2008-09 Gumi et al.          
(2012) [114]  
NA 260 
presumptive 
TB cases 
157 7 M. flavescens Molecular  
(Sequencing of 
16S rRNA  
gene) 
 
2.7 NA No NA 
 
Ghana 2013-14 Bjerrum et al. 
(2016) [103]  
 
≥18  473         
HIV 
infected 
adults 
60 38 M. avium complex         
M. chelonae                
M. simiae                
M. fortuitum                 
 
Molecular 
(sequencing of 
16S rRNA gene) 
8.0 All HIV 
infected 
No HIV 
infection and 
age 
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Kenya 2007-09 Nyamogoba et 
al.   (2012) 
[108]  
≥0 872 
presumptive 
TB cases 
346 15 M. fortuitum           
M. peregrinum       
 
Molecular        
(Genotype 
CM/As assay) 
1.7 46.7 No Previous TB 
HIV 
infection 
 
Kenya 2014-15 Limo et al.          
(2014) [109]  
≥0 210 
retreatment 
cases 
121 89 M. intracellulare     
M. abscessus           
M. fortuitum    
Molecular        
(Genotype 
CM/As assay) 
42.4 25.8 No Previous TB 
infection 
 
Mali 2004-09 Miaga et al.        
(2012) [102]  
18-73 142 
presumptive 
TB cases 
enrolled 
113 17 M. avium                
M. palustre              
M. fortuitum     
 
Molecular 
(sequencing of 
16S rRNA gene) 
12.0 17.6 Yes; 11 Previous TB 
Nigeria  2010-11 Olutayo et al. 
(2016) [92]   
 319 
presumptive 
TB cases  
122 26 NA Molecular  
(Genotype 
CM/AS assay)   
 
8.2 46.2 No HIV 
infection, age  
Nigeria 
 
2008-09 Cadmus et al. 
(2016) [93]  
NA 23 
presumptive 
cases  
11 9 M. avium complex 
               
Molecular  
(Sequencing of 
16S rRNA  
gene) 
 
39.1 NA No NA 
Nigeria 2010-11 Gambo et al. 
(2014) [94]  
NA  952 
presumptive 
TB cases  
254 65 NTM not classified Molecular 
(Genotype 
CM/AS assay) 
6.8 40.0 No HIV 
infection, TB 
Nigeria  2010-11 Gambo et al. 
(2013) [53]  
18 1603 TB 
presumptive 
TB cases 
375 69 M. intracellulare    
M. abscessus           
M. fortuitum           
M. gordonae 
 
Molecular 
(Genotype 
CM/AS assay) 
4.3 40.0 No HIV 
infection, TB 
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Nigeria 2008-09 Asuquo et al. 
(2012) [95] 
10-70 137 
presumptive 
TB cases 
81 4 M.  fortuitum          
M. avium species     
M. abscessus     
 
Molecular 
(Genotype 
CM/AS assay) 
2.9 50.0 No HIV 
infection 
Nigeria 
 
1983 Idigbe et al. 
(1986) [96] 
NA 668 
presumptive 
TB cases 
NA NA M. avium                
M. kansasii              
M. fortuitum     
 
Conventional 
biochemical 
methods 
11.0 NA NA NA 
 
 
 
Nigeria 1982-93 Idigbe et al. 
(1995) [97]  
NA NA NA NA M. avium                
M. kansasii              
M. xenopi                
M. fortuitum      
 
Conventional 
biochemical 
methods 
NA NA No NA 
Nigeria NA Mawak et al. 
(2006) [98]  
≥14 329 
presumptive 
cases 
50 15 M. avium                 
M. kansasii              
M. fortuitum     
 
Conventional 
biochemical 
methods 
4.6 NA No NA 
Nigeria 2007-09 Daniel et al. 
(2011) [99]  
25-80 102 TB 
patients (41 
new s+ and 
61s+ 
retreatment 
cases) 
70 7 M. fortuitum            
M. intracellulare     
M. chelonae    
 
Conventional 
biochemical 
methods 
6.9 15.0 No Previous TB 
Nigeria NA Allana et al. 
(1991) [100]  
NA NA NA NA M. avium                 
M. kansasii              
M. fortuitum     
 
Conventional 
biochemical 
methods 
NA NA NA NA 
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Nigeria 1963 Beer et al.    
(1965) [101]  
≥1 NA 2682 149 Runyon 111 and 1V 
organisms 
Conventional 
biochemical 
methods 
6.0 NA No Previous TB 
South 
Africa 
2006-07 Clare et al.          
(2015) [29]  
Median 
age-44 
2496   
presumptive 
TB cases 
421 232 M. kansasii             
M. gordonae 
Conventional 
biochemical 
methods 
9.3 31.9 No HIV 
infection 
South 
Africa 
1996-97 Corbett et al.        
(1999) [117]  
NA TB 
presumptive 
cases 
NA 118 M. kansasii             
M. fortuitum           
M. scrofulaceum 
Conventional 
biochemical 
methods 
NA 34.0 Yes; 32 Previous TB, 
silicosis 
South 
Africa 
1993-96 Corbett et al.       
(1999) [38]  
≥18 594 mine 
workers 
NA 406 
NTM 
M. kansasii             
M. fortuitum           
M. avium complex 
Conventional 
biochemical 
methods 
68.4 13.1 Yes; 206 HIV 
infection, 
silicosis 
South 
Africa 
1993-96 Corbett et al.       
(1999) [119]  
≥18 243 NTM 
infected 
suspects  
92 243 M. kansasii             
M. fortuitum                      
M. intracellulare 
Conventional 
biochemical 
methods 
100 NA No Previous TB, 
silicosis 
South 
Africa  
1993-96 Corbett et al.       
(1999) [118]  
≥18 406 gold 
miners 
NA 261 
NTM 
patient
s 
M. kansasii             
M. scrofulaceum 
Conventional 
biochemical 
methods 
64.3 NA No 
 
Previous TB, 
HIV 
infection 
South 
Africa 
2001-05 Hartherill et al.    
(2006) [120] 
18 
(13-
23) 
month
s 
1732 
presumptive 
TB cases 
94 109 M. intracellulare    
M. gastri                  
M. avium       
 
Molecular 
(RFPCR of 65 
KD hsp gene) 
6.3 4.2 Yes; 8 Previous TB 
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South 
Africa 
 
2009 Sookan et al.       
(2014) [121]  
NA 200 NTM 
suspects 
NA 133 
NTM 
patient
s 
M. avium complex.         
M. RGM                 
M. gordonae                 
 
Molecular        
(Genotype 
CM/AS assay) 
66.5 NA No NA 
South 
Africa 
2008 Hoefsloot et al.    
(2013) [13]  
NA NA NA 5646 
NTM 
patient
s 
MAC                       
M. kansasii              
M. scrofulaceum     
M. gordonae 
Molecular and 
biochemical 
methods 
NA NA NA NA 
Tanzania 2012-13 Hoza et al.   
(2016) [9]  
40      
7-88 
372 
presumptive 
TB cases 
85 36 M. gordonae            
M. interjectum         
M. avium complex 
M. scrofulaceum 
Molecular        
(Genotype 
CM/AS assay) 
9.7 33 No HIV 
infection and   
age 
Tanzania 2011 Haraka et al.       
(2012) [113]  
35 1 HIV 
negative 
patient with 
prior TB 
NA 1 M. intracellulare Molecular        
(Genotype 
CM/AS assay) 
100 100 Yes;1 Previous TB 
Tanzania  2001-13 Katale et al.        
(2014) [112]  
NA 472 
presumptive 
TB cases 
NA 12 M. chelonae           
M. abscessus           
M. spaghni      
 
Molecular  
(Sequencing of 
16S rRNA  
gene) 
 
2.5 NA No NA 
Uganda 2009 Asimwe et al.      
(2013) [110]  
12-18 2200 (710 
infants and 
1490 
adolescents 
presumptive 
TB cases) 
8 95 M. fortuitum           
M. szulgai                
M. gordonae     
Molecular        
(Genotype 
CM/As assay) 
4.3 NA No NA 
Uganda 2012-13 Bainomugisa et 
al.  (2013) [111]  
 
NA 241 
presumptive 
TB cases 
95 14 M. avium                
M. kansasii        
 
Molecular 
(Light cycler) 
5.8 NA No NA 
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Zambia 2009-12 Mwikuma et al. 
(2015) [105]  
NA 91 NTM 
suspected 
isolates 
NA 54 M. intracellulare    
M. lentiflavum.       
M. avium         
 
Molecular        
(Genotype 
CM/As assay) 
59.3 NA No NA 
Zambia NA Kapta et al.  
(2015) [104]  
≥1 6123 
presumptive 
TB cases 
enrolled 
265 923 NTM not identified Immunochroma
tography assay 
(Capilia 
TAUNS 
method) 
15.1 5.8 No TB and HIV 
infection 
Zambia 2001 Buijtels et al. 
(2010) [69] 
≥15 167 
chronically 
ill patients 
74 93 M. intracellulare    
M. lentiflavum        
M. chelonae         
 
Molecular  
(Sequencing of 
16S rRNA  
gene) 
 
55.6 79.0 Yes; 7 Previous TB 
HIV 
infection 
Zambia 2001 Buijtels et al. 
(2005) [69]  
≥25 4 
presumptive 
TB cases  
NA 4 M. lentiflavum         
M. goodie        
 
Molecular  
(Sequencing of 
16S rRNA  
gene) 
 
100.0 33.0 No HIV 
infection, 
damaged 
lungs  
Zambia 2011-12 Malama et al. 
(2014) [107]  
NA 100 
presumptive 
TB cases  
46 9 M. intracellulare     
M. abscessus           
M. chimera        
 
Molecular  
(Sequencing of 
16S rRNA  
gene) 
 
9.0 NA NA NA 
Zambia 2002-03 Buijtels et al. 
(2009) [10] 
≥15 565 (180 
patients and 
385 
controls) 
205 93 M. intracellulare     
M. lentiflavum.       
M. avium         
 
Molecular  
(Sequencing of 
16S rRNA  
gene) 
 
16.5 45.6 Yes; 1 Previous TB 
HIV 
infection, and 
use of tap 
water 
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Table 5: Non-tuberculous mycobacteria species isolated from sub-Saharan Africa, 1965-
2015‡ 
Non-tuberculous 
mycobacteria species 
Prior 2010 
Biochemical 
identification methods 
After 2010 
Molecular 
identification methods  
Previously associated 
with disease 
M. intracellulare Y Y Y 
M. avium Y Y Y 
M. kansasii Y Y Y 
M. chelonae Y Y Y 
M. abscessus Y Y Y 
M. fortuitum Y Y Y 
M. scrofulaceum Y Y Y 
M. lentiflavum Y Y Y 
M. interjectum Y Y Y 
M. peregrinum Y Y N 
M. gordonae Y Y N 
M. xenopi Y Y Y 
M. malmoense Y Y Y 
M. moriokaense Y Y N 
M. kumamotonense N Y N 
M. kubicae Y Y N 
M. gordonae Y Y N 
M. simiae Y Y Y 
M. palustre Y Y Y 
M. indicus pranii N Y N 
M. elephantis N Y N 
M. flavascens Y Y N 
M. bouchedurhonense N Y N 
M. chimera N Y Y 
M. europaeum N Y N 
M. neoaurum N Y N 
M. asiaticum Y Y N 
M. nonchromogenicum N Y N 
M. gastri Y Y N 
M. nebraskense Y Y N 
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M. confluentis Y Y N 
M. porcinum Y Y Y 
M. terrae Y Y N 
M. seoulense Y Y N 
M. engbackii Y Y N 
M. parascrofulaceum Y Y N 
M. triviale Y Y N 
M. scrofulaceum Y Y Y 
M. szulgai Y Y Y 
M. heckeshornense Y Y N 
M. poriferae Y Y N 
M. spaghni Y Y N 
M. goodie Y Y N 
M. aurum Y Y N 
M. conspicum Y Y N 
M. mucogenicum Y Y N 
M. rhodesia Y Y N 
M. gilvum Y Y N 
M. genevanse N Y N 
M. intermidium N Y N 
M. fortuitum 11/M. 
magaritense 
N Y Y 
Y=isolated N=not isolated 
    
3.4.2 Synthesis of results  
3.4.2.1 Epidemiology of Non-tuberculous Mycobacteria  
The overall prevalence of NTM in pulmonary samples in sub-Saharan Africa derived from all 
37 papers reviewed was 7.5% (95% CI: 7.2% - 7.8%). The median age of participants was 35 
(Interquartile range, IQR 16 - 80) years based on 17 of 37 studies with age data. Majority 
(2325 [75.0%] of 3096) of subjects with NTM were males. Patients in 12 of 37 studies 
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(32.4%) had a previous history of pulmonary tuberculosis and only 15 (40.5%) studies 
investigated co-infection with HIV.  
MAC species accounted for 28.0% (95% CI: 27.2 – 28.9%) of all NTM isolated and was the 
most frequently encountered NTM found in pulmonary samples in 19 of 37 studies. The 
prevalence of MAC ranged from 15.0% (95% CI: 5.05 – 25.0%) in Tanzania to 57.8% (95% 
CI: 36.3 – 76.9%) in Mali as shown in Figure 11 (along with country HIV prevalence in the 
legend [122]). There was regional variability in the distribution of NTM for example; 76.4% 
(95% CI: 74.8 – 77.9%) i.e. 2,355 of 3,084 MAC isolates from South Africa were M. 
intracellulare, while all MAC isolates from Mali were M. avium. Similarly, while M. kansasii 
was the third most isolated NTM in sub-Saharan Africa overall (4.7% [95% CI: 4.3 – 5.1%]), 
it was the top NTM in 5 (62.5%) of 8 studies in South africa. Other slow growing 
mycobacteria isolates, though less prevalent than MAC, were M. scrofulaceum 7.0% (95% 
CI: 6.4 – 7.5%) and M. gordonae 3.8% (95% CI: 3.4 – 4.3%). The rapidly growing 
mycobacteria i.e. M. fortuitum, M. chelonae, and M. abscessus accounted for just 1.2% (95% 
CI: 1.0 – 1.4%) of all NTM isolates from sub-Saharan Africa. Rapidly growing mycobacteria 
were reported predominantly from eastern African countries with M. fortuitum (43.0% [95% 
CI: 34.4 – 53.2%]) and M. abscessus (16.0% [95% CI: 9.4 – 25.9%]) as the top and second 
ranked NTM isolates from Uganda and Kenya respectively.  
Among the 70.8% (6357 of 8980) fully speciated isolates in this review, there were 0.9% (56) 
M. lentiflavum, 0.9% (55) M. malmoense, 0.7% (43) M. xenopi, 0.4% (24) M. gastri, 0.3% 
(16) M. szulgai, 0.2% (15) M. flavescens, and 0.2% (11) M. interjectum. Unfortunately, 
29.2% (95% CI: 28.1 – 30.1%) i.e. 2,623 of all 8,980 NTM isolates were not identified to 
species level. 
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Figure 11: The distribution of the top four NTM identified from pulmonary samples 
with national HIV prevalence data: Mali (HIV 1.4%), Ghana (HIV 1.3%), Nigeria (HIV 
3.1%), Uganda (HIV 7.1%), Kenya (HIV 5.9%), Tanzania (HIV 4.7%), Zambia (HIV 
12.9%), and Republic of South Arica (HIV 19.2%), without taking into account of 
clinical relevance [123].  
 
3.4.2.2 Pulmonary Non-tuberculous Mycobacteria Disease 
Only 7 (19.0%) of the 37 articles investigated the clinical relevance of isolated NTM. 
Although these studies had 3,319 participants, only 962 (28.9%) had sufficient information to 
apply the ATS/IDSA criteria and of these, 266 (27.7%) met the definition of pulmonary NTM 
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disease. M. kansasii, isolated in 184 (69.2%) of 266 cases, was the most predominant cause 
of confirmed pulmonary NTM disease, followed by M. scrofulaceum (13.9%), MAC 
(13.5%), M. lentiflavum (1.9%), M. simiae (0.8%), M. palustre (0.4%) and M. abscessus 
(0.4%). Figure 12 shows the distribution of NTM species causing pulmonary NTM disease in 
sub-Saharan Africa by country. The studies investigating the clinical relevance of NTM 
isolates varied substantially in design, participant characteristics and background HIV 
prevalence (see Table 4). They ranged from a Zambian study that evaluated the clinical 
relevance of NTM isolated from 180 chronically ill patients and 385 healthy controls and 
found only 1.1% of isolates were clinically relevant [10] to a Malian study in patients with 
primary and chronic pulmonary tuberculosis where 57.9% of isolated NTM were clinically 
relevant [102]. 
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Figure 12: Non-tuberculous mycobacteria species causing pulmonary disease found in 
respiratory specimens in sub-Saharan Africa.  
 
3.4.2.3 Clinical and Radiological Signs and Associated Morbidities  
Of 3096 participants with NTM isolated, 80.7% (2498) and 87.5% (2,709) had clinical and 
radiological information respectively [38, 69, 79, 102, 113, 117, 120]. Clinical characteristics 
for NTM subjects closely mimicked those of pulmonary tuberculosis, as summarized in Table 
4. There were radiological abnormalities in 79.0% (2141) of 2709 subjects, while 21.0% 
(568) had normal chest radiographs. Of the 512 with prior lung disease, 87.1% (446) had a 
history of tuberculosis and 12.9% (66) had bronchiectasis. In those with concurrent 
conditions, 50.2% (442) of 880 were co infected with HIV, 28.2% (248) reported 
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gastrointestinal diseases and 8.6% (76) complained of body weakness. Other characteristics 
are shown on Table 6.  
Table 6: Clinical and radiographic characteristics for patients with pulmonary non-
tuberculous mycobacteria regardless of clinical relevance in sub-Saharan Africa (n= 
3096) 
Characteristic Numbers (%) 
Clinical signs n=2, 498 
Cough ≥2 weeks  950 (38.0%) 
Chest pain  684 (27.3%) 
Significant weight loss  546 (21.9%) 
Fever≥2 455 (18.2%) 
Night sweats 211(8.4%) 
Haemoptysis  
Dyspnoea  
27 (1.1%) 
19 (0.8%) 
  
Previous lung disease n= 512 
Bronchiectasis 66 (12.9%) 
Tuberculosis 446 (87.1%) 
  
Radiographic findings n= 2709  
Abnormal, suggestive of TB 1009 (37.2%) 
No pathological changes 568 (20.9%) 
Tuberculosis  446 (16.5%) 
Nodules 203 (7.5%) 
Fibrosis 140 (5.2%) 
Cavitation 127 (4.7%) 
Prior focal radiological scarring 107 (4.0%) 
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Bronchiectasis 66 (2.4%) 
Abnormal, not consistent with TB 24 (0.9%) 
Milliary TB 19 (0.7%) 
 
 
Concurrent conditions n=880 
HIV infection  442 (50.2%) 
Gastrointestinal disease 248 (28.2%) 
Weakness 76 (8.6%) 
Lymph node enlargement 52 (6.0%) 
Splenomegaly 21 (2.4%) 
Diabetes mellitus 22 (2.5%) 
Hepatomegaly 19 (2.2%) 
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3.5 Discussion 
We provide an overview of the epidemiology and geographical distribution of NTM species 
isolated from pulmonary samples in sub-Saharan Africa. To our knowledge, this is the first 
comprehensive review of pulmonary NTM in this part of the world. Similar to reviews by 
other authors, our findings suggest diversity in prevalent NTM species, geographical 
variation in NTM distribution and their clinical relevance across the sub-continent [37].  
The global collection of NTM isolated from pulmonary samples reported by Hoefsloot et al. 
[13] in 2008 included isolates from only one sub-Saharan Africa country, South Africa. The 
update in 2013 by Kendall et al. did not improve significantly on the earlier review with 
respect to additional African NTM isolates [7]. Despite the relative scarcity of local data, it is 
important to highlight that this review is the first to include NTM data for nine countries in 
sub Saharan Africa.  
Overall, we found a predominance of MAC from pulmonary samples in countries of Western, 
Eastern and Southern Africa. M. scrofulaceum and M. kansasii were predominant in Southern 
Africa and the rapidly growing mycobacteria (M. abscessus, M. fortuitum and M. chelonae) 
in Eastern Africa. These findings are consistent with the predominance of MAC in the 
epidemiology of NTM in North America [2, 7, 67] Europe [124] Australia [125] and East 
Asia [31]. The relative preponderance of the two members of the MAC family also varied by 
region with M. intracellulare predominating in South Africa while all MAC isolates from 
Mali were M. avium. However, the South African study had a much bigger sample size 
compared to the Malian study. While MAC was the most frequently implicated NTM in 
colonisation, M. kansasii was the most common in pulmonary NTM disease. The dominance 
of M. kansasii as well as the presence of M. scrofulaceum in South Africa was speculated to 
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be linked to mining activities and significant urbanisation in the country, resulting in a socio-
economically disadvantaged population [28, 33, 126] working in the mines, and frequently 
suffering from silicosis, while living in poor, overcrowded environments.. 
When the South Africa pulmonary NTM data is excluded, MAC is the major cause of  
pulmonary NTM as reported in North America, Europe, Australia and Asia [7]. Because 
relatively few studies in this review applied the ATS/IDSA criteria for confirmation of 
pulmonary NTM disease, it is difficult to reach conclusions regarding the dominant NTM 
species causing pulmonary disease in sub-Saharan Africa.  
In contrast to observations from other parts of the world, especially in Europe, where M. 
malmoense and M. xenopi are well known for causing pulmonary NTM disease [2, 27] these 
NTM were not represented in the limited number of studies reviewed here. M. xenopi was 
rare in sub-Saharan Africa which is not unexpected considering its association with hot water 
delivery systems that are less developed in sub-Saharan Africa compared to industrialised 
countries.  
Pulmonary NTM was commonly associated with a history of previous pulmonary 
tuberculosis in sub-Saharan Africa compared to Europe and North America. This is not 
surprising given the high incidence of MTBC disease in sub-Saharan Africa [127]. 
Pulmonary tuberculosis is associated with significant sequelae that have not been adequately 
studied in sub-Saharan Africa. The associated structural lung damage, chronic pulmonary 
obstructive disease most likely favour colonization by NTM and other pathogens [2]. It is 
also likely that the increasing isolation of NTM has come from investigation of patients with 
chronic pulmonary disease including those complicating previous pulmonary tuberculosis 
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[53, 102]. In light of this, the clinical, radiological and microbiologic criteria of the 
ATS\IDSA is important for distinguishing colonization from pulmonary NTM, particularly in 
sub-Saharan Africa that is endemic for MTBC [55]. 
Many rarely isolated NTM were also identified in presumptive tuberculosis patients, for 
example M. genavense, M. gilvum, M. intermedium, M. poriferae, M. spaghni, M. 
interjectum, M. peregrinum, M. moriokaense, M. kumamotonense and M. kubicae. Although 
some of these species have also been isolated in other parts of the world from pulmonary 
samples in patients with chronic bronchitis, pulmonary tuberculosis, sub-acute pneumonia 
and healed tuberculosis[128, 129] it is currently unclear what role they play in the aetiology 
of pulmonary disease in Africa. 
The HIV-driven increase in the risk of tuberculosis disease in sub-Saharan Africa has been 
well described and for NTM, MAC is a particularly well described opportunistic infection in 
patients with AIDS. We found almost half of all cases of confirmed pulmonary NTM were 
also HIV co-infected. This suggests the possibility of HIV attributable pulmonary NTM 
beyond the now familiar disseminated MAC disease often seen in persons with AIDS.  
Persons with pulmonary NTM disease in sub-Saharan Africa are younger than observed in 
North America, Europe and Australia where increasing age (≥50 years), structural lung 
damage, immunosuppressive chemotherapy for cancer, autoimmune and rheumatoid 
conditions are the most frequently reported risk factors for this disease [2, 7, 39, 42]. Given 
the younger age and higher burden of pulmonary tuberculosis and HIV co-infection in sub-
Saharan Africa, it is not surprising that we found pulmonary NTM disease mostly in the 33-
44 year-age group.  
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Our review has a number of limitations: we only searched for English language-articles. 
Given the numbers of Francophone countries in sub-Saharan Africa, French-language 
publications may have been missed. In addition, our assessment of the clinical relevance of 
isolated NTM was not as comprehensive as desired because majority of the studies did not 
collect the detailed clinical, radiological and microbiological data required to do this. We also 
could not report the full diversity of NTM in colonization and disease because almost 30% of 
all isolates were not fully identified to species level. Since the studies reviewed came from 
varied time periods during which laboratory procedures for ascertainment differed, we cannot 
exclude the possibility of laboratory procedures before and/or after year 2000 selecting for 
particular NTM species whilst inhibiting others [79]. For example, the wider usage of 
sensitive liquid culture media could in theory have selected for specific NTM species. 
Similarly, the increasing use of molecular methods for identification of current and historical 
isolates, especially for the MAC and rapidly growing mycobacteria groups, could underpin 
the changes to NTM taxonomy over time [22, 130, 131]. However, we think our results were 
not significantly affected because the distribution of NTM species identified in the periods 
before and after 2010 were similar. It was also not possible to link the pulmonary NTM 
reported to prevalent NTM species in the environment so as to reach conclusions regarding 
the geographical variation in NTM because data on environmental NTM in sub-Saharan 
Africa is even more sparse than for human studies. Given the heterogeneity of studies 
included in this review including laboratory methods and quality standards, some of the NTM 
reported here may be due to contamination especially for NTM like M.flavescens that are 
frequent laboratory contaminants. It is possible for example that all 7 M.flavescens reported 
were contaminants. In more than half of 26 studies that used molecular techniques to identify 
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NTM, 16s rDNA sequencing was used. However, this method has a limitation in that it is not 
fully capable of distinguishing between all the different NTM species for example M. 
abscessus and M. chelonae. Therefore, it is possible some species have been misidentified or 
misclassified in these studies. 
To conclude, we have provided the first detailed review of pulmonary NTM in sub-Saharan 
Africa. This review highlights the contribution of NTM to the aetiology of tuberculous-like 
pulmonary disease in the sub-continent. It also suggests their presence as commensals in 
pulmonary samples may confound the diagnosis of pulmonary tuberculosis, especially in 
those with previous history of tuberculosis and/or other chronic respiratory conditions.  
Additional research and surveillance is required for investigation of the full contribution of 
NTM to pulmonary disease, to describe the full repertoire of prevalent and incident NTM, 
and to determine the role of risk factors (particularly HIV/AIDS) for colonization and/or 
disease. Given the risk of over diagnosis of NTM in pulmonary samples as tuberculosis 
disease, resulting in repeated courses of treatment in previously treated tuberculosis patients, 
investments in and development of point of care diagnostics for NTM are required.
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4 Epidemiology of Non-tuberculous Mycobacteria in The 
Gambia-Pulmonary Carriage and Disease 
During the nationwide Gambian Survey of Tuberculosis Prevalence (GAMSTEP) that 
described the population prevalence of pulmonary MTBC disease [132], significant numbers 
of AFB positive sputum cultures that were negative for MTBC [according to the BD MGIT 
TM TBc Identification (Becton, Dickinson and Company, USA) rapid test] were considered 
suspicious for NTM. The TB prevalence survey at the Medical Research Council Unit The 
Gambia (MRCG), provided a unique opportunity to estimate the population prevalence of 
NTM in pulmonary samples, determine the prevalence of confirmed/clinical pulmonary NTM 
disease and investigate associated risk factors in the general population.  
This is the first study in The Gambia to report on NTM species isolated from pulmonary 
samples and their clinical relevance. 
4.1 Study Hypothesis 
Non-tuberculous mycobacteria are prevalent in sputum samples of a population sample in 
The Gambia and can cause pulmonary NTM dsease.. 
4.2 Aims of Study 
The overall aim of the study is to estimate the prevalence and predictors of NTM in 
colonisation and disease in pulmonary samples of a subset of The Gambia population.  
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4.3 Primary Objectives: 
1. To speciate suspected NTM from sputum samples of a representative population of 
The Gambia using the 16S rRNA gene sequencing analysis technique. 
2. To determine the prevalence, and explore the pattern of occurrence, of NTM in four 
participant groupings with the following features:  
 No respiratory symptoms and abnormal CXR 
 No respiratory symptoms and normal CXR 
 Respiratory symptoms and abnormal CXR 
 Respiratory symptoms and normal CXR 
3. To explore the risk factors (e.g. age, gender, clinical and radiological features, urban 
versus rural residence and history of previous pulmonary TB) for NTM colonisation 
and disease. 
4. To explore the clinical relevance of isolated pulmonary NTM using the American 
Thoracic Society/Infectious Disease Society of America diagnostic criteria for 
pulmonary NTM disease. 
4.4 Materials and Methods 
4.4.1 Ethical Approval 
The MRCG Scientific Coordinating Committee (SCC) and the MRCG/Gambia Government 
Joint Ethics Committee approved this study (SCC number 1371).  
4.4.2 Study Area, Subjects and Samples  
Following prerequisite SCC and ethical approvals for Gambian Survey of TB Prevalence, all 
fieldwork, including collection of demographic and clinical data (including CXR findings), 
Non-tuberculous Mycobacteria in The Gambia  
 
Page | 77 
    
CHAPTER FOUR 
and laboratory work were completed at the MRCG TB diagnostic and research molecular 
biology laboratories as already described [132]. This MPhil project started with retrieval of 
archived sputa from the freezer and the parent study, the Gambian Survey of TB Prevalence, 
was not part of my MPhil.  
On conclusion of the parent survey, 903 suspected cases of NTM were identified from 
decontaminated sputa that yielded  AFB positive culture yet were negative for MTBC 
following testing with the rapid identification assay, BD MGIT TM TBc Identification 
(Becton, Dickinson and Company, USA). This rapid identification assay tests for the MTBC-
specific Mycobacterium Protein Target 64 (MPT64) antigen. All 903 were selected for 
inclusion in this study. However, following retrieval of stored sputa, only 575 (63.7%) of 903 
samples yielded AFB positive cultures, all of which were selected for analysis. 
This study population was categorized into 4 groups as shown in Table 7. The second 
category of participants screened positive for CXR features suggestive of TB during field 
screening in the parent study but were subsequently re-classified as normal by an expert 
radiology panel. As a result, they became a convenient control group (asymptomatic for TB 
and normal CXR) for this project. I was blinded to these categories while working on the 
specimens.
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Table 7: Categorization of suspected NTM study participants  
Category Classification of Participants Number of available participants with suspected 
NTM cultures 
GAMSTEP (903) NTM study (575) 
1  No respiratory symptoms  
and abnormal CXR  
408 266 
2  No Respiratory symptoms  
with a normal CXR  
22 16 
3  Respiratory symptoms  
and abnormal CXR  
199 133 
4  Respiratory symptoms  
and normal CXR  
274 160 
Total   
903 575 
 
 
4.5 Laboratory Methods 
4.5.1 Smear Microscopy, Decontamination and Liquid Cultures as part of 
Gambian Survey of Tuberculosis Prevalence (GAMSTEP) Activities 
Fluorescent microscopy was performed on all sputum samples with 0.5% Auramine stain in 
the parent study. The sputa were then decontaminated by treating them with 1.0% N-acetyl-
L-cysteine (NALC), 4.0% sodium hydroxide and 2.9% sodium citrate. They were incubated 
in the BACTEC MGIT 960™ system (Becton Dickinson Diagnostic Instrument Systems) as 
described by Rodrigues et al. [133]. Samples without any growth after 42 days of incubation 
were removed and classified as negative. 
Samples with growth were removed from the machine and inoculated on blood agar to check 
for contamination. Microscopy with ZN staining was then performed to check for the 
presence of AFB. Non-AFB samples were considered contaminants and excluded from the 
study. BACTEC MGIT positive cultures that tested positive for AFB on ZN microscopy were 
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further tested with the TBc rapid antigen assay to confirm MTBC. Where MTBC were 
confirmed, cultures were further sub-cultured onto Lowenstein Jensen (LJ) media. 
Suspensions were made from matured colonies in tryptone soya broth (soybean casein digest 
medium) and stored at -70oC [132]. 
4.5.2 NTM Identification and Characterization 
4.5.2.1 Culture of Decontaminated Sputum Samples  
In the parent study, AFB positive IBD rapid test negative cultures were not stored. I therefore 
had to use the archived, decontaminated sputa from which these suspected NTM cultures 
were originally identified for this work. MGIT tubes containing 7mL of modified 
Middlebrook 7H9 broth base were used for the detection and recovery of NTM. These tubes 
were supplemented with 0.8mL of BACTECTM MGITTM growth supplement (to provide 
substances essential for the rapid growth of mycobacteria) and BBLTM MGITTM PANTATM 
antibiotic mixture (to inhibit growth of non- mycobacterial agents) before inoculation with 
0.5mL of stored, decontaminated sputum samples from which suspected NTM were 
identified in GAMSTEP. MGIT tubes were incubated at 37oC in the automated BACTEC 
MGIT 960TM system (Becton Dickinson Diagnostic Instrument Systems) until flagged as 
positive or negative after 42 days. All AFB positive cultures were classified as suspected 
NTM while non-AFB cultures were considered contaminants and excluded from the study.  
4.5.2.2 16S Ribosomal Ribonucleic Acid (16S rRNA) gene PCRs  
In preparation for 16S rRNA gene PCRs, mycobacterial DNA was extracted from MGIT 
cultures by the boiled lysate method described by Wade et al [134]. Briefly, 0.5 mL of culture 
was centrifuged at 10,000 rpm for 15 minutes. 
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The resulting pellets were resuspended in 0.1mL sterile Tris ethylene diamine tetra acetic 
acid (TE) buffer® (Sigma Aldrich, St. Louis, Missouri, United States) and suspensions 
heated in a heat block at 99 oC for 20 minutes followed by sonication for 15 minutes. Tubes 
were then spun at 14,000 rpm for 5 minutes following which 50 μl aliquots of the supernatant 
were transferred to sterile tubes and stored at - 20°C until PCRs were performed. 
4.5.2.3 Primers 
With standard mycobacteria genus-specific primers (Metabion international Martinsried/ 
Deutschland), a 960 bp sequence of the mycobacterial 16S rRNA gene was amplified as 
earlier described by Böddinghaus et al. [135]. Concentrated stock aliquots (100 μM) of 
primers P1 and P2 new [136]. were reconstituted with nuclease-free water. For working 
solutions, stock primers were diluted 10 times (1:10 dilutions) to give a 10 μM primer 
working concentration, then both stock and working solutions were stored at -20°C (Table 8). 
Table 8: Primers for NTM identification in study 
Primer names Sequence Melting  
temperature 
(Tm) 
Expected amplicon       
band size (bp) 
P1 (Forward primer) 
5’-TGCTTAACACATGCAAGTCG-3’ 
 
56°C  ~ 960bp 
P2 new  (Reverse primer) 
5’-TCTCTAGACGCGTCCTGTGC -3’ 
63°C  ~ 960bp 
 
4.5.2.4 Optimization Experiments and 16S rRNA gene Amplification 
Optimal reagent/solution concentrations, assay amplification conditions (cycling 
temperatures/numbers) and equipment required to amplify the mycobacterial 16S rRNA gene 
were determined prior to NTM identification and characterization. In these experiments, 
various primer concentrations of P1 and P2 new (0.08 μM, 0.2 μM 0.35 µM) were tested 
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against an annealing temperature gradient of 52oC to 60oC. A 2.5 μL aliquot of DNA from a 
mycobacterial reference strain (M. tuberculosis H37RV) was used in a total reaction volume 
of 25 μL containing 2.5 μL of 10X buffer (containing 1.5 mM magnesium chloride solution), 
0.5 μL of 10 mM deoxyribonucleotide triphosphate (dNTPs), 0.08 to 0.35 μL of 10 μM P1/P2 
primers, and 0.2 μL of 5.0 U/μl of Taq DNA polymerase (Qiagen).  
The optimal PCR conditions identified were: one cycle of denaturation at 95°C for 5 minutes, 
45 cycles consisting of denaturation at 95°C for 45 seconds, annealing at 52°C to 60°C for 45 
seconds, an extension at 72°C for 45 seconds and a final cycle of extension at 72°C for 10 
minutes. Amplification was carried out in a 96-well microtiter plate using a gradient 
thermocycler. Gel electrophoresis was carried out for detection of PCR amplification 
products on a 1% (w/v) agarose gel. The set of amplification conditions which produced the 
brightest, single amplicon band of ~960 bp were chosen as the optimal PCR conditions for 
this project.  PCRs were performed in a 25 μl reaction volume under the PCR conditions 
outlined on Table 9. All PCR products were stored at -20 oC for further laboratory processin 
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Table 9: 16S rRNA gene PCR reaction mix 
Reagent/solution  Volume (μl) for one 
reaction 
Final Concentrations 
PCR water 18.9  
10X buffer MgCl2 (1.5 mM) 2.5 1X 
dNTPs (10 mM) 0.5 0.2 mM 
Primer F (10 μM) 0.2 0.08 μM 
Primer R (10 μM) 0.2 0.08 μM 
Taq (5 U/μl) 0.2 0.04 U/μl 
gDNA (ng) 2.5  
Total 25  
 
4.5.2.5 Detection of PCR Amplification 
Agarose gel electrophoresis was used to check if desired PCR products (amplicons) were 
amplified and to estimate amplicon sizes. Five microliter of PCR products were loaded on 
1% (w/v) agarose gel slabs stained with ethidium bromide (5 μg/ml) and analysed by gel 
electrophoresis in 1 x TAE buffer (40 mM Tris, 20 mM of glacial acetic acid, 1 mM EDTA, 
pH 8.0) for 35 minutes at 100 Volts. The size of amplicons was estimated by comparison 
with 1 Kbp DNA ladder (BioLabs, New England) and visualized using Bio-Rad Molecular 
Imaging System (USA). 
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4.5.2.6 Purification of PCR Products and Sequencing 
Amplicons from suspected NTM cultures amplified as mycobacteria were cleaned using 
exonuclease and shrimp alkaline phosphatase (EXOSAP) to remove nonspecific PCR 
products. Briefly, 1l of shrimp alkaline phosphatase and 1 l of exonuclease were added 
into a sterile 1.5 ml micro centrifuge tube containing 10 l of nuclease-free water. The 
suspension was mixed by a gentle tap and then 10 μl dispensed into wells of a 96 well plate. 
10 l samples of each amplicon was dispensed into a well and mixed by up and downward 
pipetting using filter-barrier pipette tips. The plate was sealed with an adhesive film and spun 
briefly. EXOSAP reaction was carried out in a thermal cycler in an initial step at 37°C for 15 
minutes followed by another step at 80°C for 20 minutes. Cleaned PCR products were stored 
at -20°C until sequencing reactions were carried out. 
Cycle sequencing reactions were done in 10 μl reaction volumes containing 4.36 μl nuclease-
free H2O, 2 μl of 5X sequencing buffer, 0.64 μl of 10 μM P1 and P 2 primer each, 0.5 μl Big 
Dye (Applied Biosystems (ABI) terminator kit version 3.1 chemistry) and 2.5 μl of cleaned 
PCR product. PCR products from the cycle sequencing reaction were further purified using 
Sephadex® G-50 columns (Sigma-Aldrich). Briefly, G-50 powder was added onto a 
Multiscreen Column Loader and sprayed over to fill in the number of wells that were needed 
using a Multiscreen Loader scraper. 300 l of nuclease free water was added into each well 
and allowed to sit at room temperature for two hours and then centrifuged at 2300 rpm for 
five minutes to remove water from the G-50 column. The column was washed twice with 
nuclease-free water and centrifuged as described above. The G-50 plate was transferred to a 
sequencing plate and 11 l of PCR product added to appropriate wells. The plate was 
centrifuged at 2300 rpm for five minutes to filter out the PCR products into their 
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corresponding wells on the sequencing plate. The products were dried in a thermal cycler for 
20 minutes at 90°C. 10 μl of formamide was added into each well containing dried product. 
The plate was vortexed briefly, centrifuged briefly and products denatured at 90°C for 2 
minutes. The Sanger sequencing method using the ABI 3130x DNA analyser was used to 
determine the order of nucleotide sequence in the PCR products.    
4.5.2.7 Editing Sequence Data and NTM Identification  
Background and ambiguous non-standard nucleotides were removed and the correct DNA 
nucleotides inserted. Unknown sequences were edited in BioEdit software (version 7.2.5 Ibis 
Biosciences). Consensus sequences were computed by matching forward and reverse traces 
of each sample using SeqTrace 0.9.0 software. Filtering of low quality base calls and end 
trimming were also performed and high quality finished unknown sequences were exported 
in Fasta format for downstream analyses. 
To illustrate phylogenetic relationship of unknown sequences and subsequently identify 
them, NTM and MTBC 16S rRNA reference sequences derived from American Type Culture 
Collection (ATCC isolates) were downloaded from Gen Bank [137]. These sequences were 
aligned together with unknown sequences in BioEdit software using ClustalW2 Multiple 
Sequence Alignment tool. A Phylogenetic tree was constructed from the aligned sequences 
based on regions A and B of the Mycobacteria gene using maximum likelihood algorithm 
implemented by PhyMl (PHYlogenetic inferences using Maximum Likelihood). Unknown 
sequences were further identified based on their relatedness to NTM and MTBC reference 
strains on phylogenetic tree. 
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4.6 Quality Control Measures for Preventing Contamination  
Contamination during specimen analysis leading to false positive results can be common [2, 
27]. This phenomenon is typically caused by contamination of the specimen with NTM 
contained in non-sterile laboratory water used for preparation of reagents and solutions and/or 
cross contamination from a heavily infected specimen to other specimens being analysed at 
the same time. To avoid this kind of contamination, quality control (QC) measures were put 
in place during processing of all suspected NTM cultures to detect and exclude 
environmental NTM contamination. These included the following:  
 Aseptic mycobacteriological techniques such as use of aerosol barrier pipette tips, 
changing pipette tips between all liquid transfers, pulse centrifugation of tubes after 
vortexing to remove drops from inside of the lid and working in a biological safety 
cabinet. Hand gloves were worn throughout laboratory procedures and these were 
duly changed whenever they encountered any sample.  
 All water used was ultrapure, sterile-filtered, deionised water. Untreated laboratory 
water was NEVER used in any of the assays. All solutions/reagents employed for the 
isolation and culture of mycobacteria were sterilized either by autoclaving or filtration 
and quality controlled prior to usage.  
 For DNA extraction, negative controls (nuclease-free water) were included in each 
batch of extraction procedure to exclude NTM contamination of laboratory reagents/ 
solutions and cross contamination. 
 For the 16S rRNA gene PCRs and sequencing, non-template controls (NTC) were 
included in each batch of pre- and post-PCRs to exclude NTM contamination from 
laboratory reagents, solutions and the environment. 
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 An audit was performed in our laboratory to screen for possible sources of laboratory 
contamination. Samples of laboratory-distilled water, and all reagents and solutions 
used for identification and characterization of NTM were cultured and subjected to 
16S rRNA gene PCR. 
4.7 Analysis  
All data analyses for this study were carried out with Stata version 12 (Stata Corp, College 
Station, TX) with the help of MRCG Statistician. The main outcome of the study was the 
prevalence of NTM in the study population. NTM prevalence and other categorical variables 
were summarised using frequency counts and proportions. From the samples selected from 
the parent study, there were 328 participants with culture negative results compared to the 
original study. NTM prevalence was estimated using 2 models. Model 1: Complete case 
analysis - Here I analysed only samples that had a complete data set for all variables.                                                                                                                         
Model 2: Here I assumed the results for the 328 participants with negative cultures were truly 
negative. Results from the 2 models are presented.                                                                                       
Associations between NTM prevalence and categorical risk factors were examined in 
univariate analysis using mixed-effects logistic regression . Those reaching statistical 
significance (p<0.05) in univariate analyses were included in random effects multivariate 
logistic regression models to obtain odds ratios and their 95% confidence intervals adjusted 
for risk factors and clustering in the design of the parent study. Estimates derived from 
regression models were adjusted for urban/rural residence, gender, age and ethnicity. 
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Participants with NTM positive samples were assessed for clinically relevant disease using 
the ATS/IDSA diagnostic criteria and classified as confirmed, probable, suspected and non-
pulmonary NTM disease. 
4.8  Results 
4.8.1 Outcome of Optimisation Experiments 
Here, results of the initial optimisation and quality control for experiments for NTM 
identification, characterisation and results of 16S rRNA gene sequencing analyses are 
presented.  
Of the three primer concentrations (0.35 µM, 0.2 µM and 0.08 µM) used against a range of 
annealing temperature gradient of 52oC to 60oC, only primer concentrations of 0.08 µM 
yielded clear, sharp and bright amplification products with expected size of 960bp as shown 
in Figure 13. Sequencing of the PCR products also correctly identified NTM, positive and 
negative controls. Therefore, 0.08 µM primer concentrations with 56oC annealing 
temperatures were adopted as optimal conditions for 16S rRNA gene PCRs.  
4.8.2 Quality Control 
The quality control measures implemented were successful in preventing contamination 
because cultures of samples of distilled water, reagents and solutions used for processing and 
identification of NTM in our laboratory did not yield any NTM growth. In addition, PCR on 
these reagent samples did not amplify any DNA (see Figure 14).  
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Figure 13: Outcome of PCR optimization experiments 
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Figure 14: Quality control on positive and negative controls, reagents and solutions used for 16S rRNA gene PCRs. DNA marker - 1 
Kbp DNA marker; positive control 1- H37RV; positive control 2- BCG; sample 1- TE buffer; sample 2- laboratory distilled water; 
sample 3- Mycobacterium avium complex; negative control - Escherichia coli; TE -Tris ethylene diamine tetra acetic acid; Kbp - Kilo 
base pair; DNA - Deoxyribonucleic acid 
  
 
 
 
 
 
1.0 kbp 
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4.8.3 Demographic Characteristics of Participants  
The socio-demographic characteristics of the study population are displayed in Table 10. 
Total participants, 575 as earlier indicated provided 730 samples as shown in the CONSORT 
diagram - Figure 15. 
The  median age (Interquartile range-IQR) of participants was 55 (IQR 40 – 70) years. More 
than half were ≥55 years old. The majority of the subjects were female and lived in rural 
areas of The Gambia.  
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Figure 15: Outline of the non-tuberculous mycobacteria study in The Gambia 
 
 
903 (16.3% of 5523) Participants; 1145 samples 
 AFB+ve, rapid test negative 
 
 
 251 (43.7% of 575) Participants, 303 samples 
Mycobacteria in at least one sputum sample  
 
 229 (40.0% of 575) Participants; 273 samples 
NTM in at least one sputum sample  
 77 - MTBC 
 4 - No culture results 
 4539 - Negative cultures 
575 (63.7% of 903) Participants; 730 samples   
Complete data on MGIT cultures after growing 
stored decontaminated sputa from freezer 
 
328 (36.3% of 903) Participants; 415samples 
(Missing data on culture results) 
 
324 (56.3% 575) Participants; 427 samples  
Not mycobacteria 
 
22 Participants; 30 samples 
 5 - MTBC 
 17- mixed cultures 
 185 (80.8% of 229) Participants; 185 
samples 
NTM in one sputum sample  
 44 (19.2% of 229) Participants; 88 
samples 
NTM in both sputa  
 
5523  GAMSTEP participants  
Submitted at least one sputum sample 
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Table 10: Socio-demographic Characteristics of the Study Population (n=575) 
Characteristics 
 Presumptive NTM 
cases (n=575) (%)  
Positive for NTM 
(n=229) (%) 
Gender    
Male   246 (42.8) 88 (38.4) 
Age group (years)    
        15-24   41 (7.1) 7 (3.1) 
         25-34   42 (7.3) 19 (8.3) 
         35-44  84 (14.6) 38 (16.6) 
         45-54  100 (17.4) 39 (17.0) 
          55-64  106 (18.4) 38 (16.6) 
          ≥65  202 (35.1) 88 (38.4) 
    
Clinical symptoms    
          Fever  260 (45.2) 107 (46.7) 
          Cough  227 (39.5) 78 (34.1) 
          Night sweats  64 (11.1) 29 (12.7) 
          Prior tuberculosis  40 (7.0) 12 (5.2) 
Ethnicity    
          Mandinka  216 (37.6) 79 (34.5) 
          Wolof  100  (17.4) 54 (23.6) 
          Fula  139 (24.2) 57 (24.9) 
          Others  120 (26.9) 39 (17.0) 
Region of country    
         West Coast    109 (19.0) 19 (8.3) 
         Central River   163 (28.4) 93 (40.6) 
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         Greater Banjul   97 (16.8) 29 (12.3) 
         North Bank   101 (17.6) 50 (21.8) 
         Upper River   83 (14.3) 35 (15.3) 
         Lower river   22 (3.8) 3 (1.3) 
Location    
          Rural   400 (69.6) 172 (75.1) 
          Urban   175 (30.4) 57 (24.9) 
Occupation      
          Professional  70 (12.7) 21 (9.2) 
          Service worker  30 (5.2) 10 (4.4) 
          Agriculture  222 (38.6) 93 (40.6) 
          Dependant  247 (43.0) 104 (45.4) 
          Others  6 (1.0) 1 (0.4) 
Education    
           Read in English/Arabic  511 (88.9) 214 (93.5) 
           Primary  41 (7.1) 11 (4.8) 
           High school/Diploma/University        23 (4.0) 4 (1.8) 
Chest X ray    
           Normal  191 (33.2) 77 (33.6) 
           Abnormal  384 (67.2) 152 (66.4) 
Participant categories    
No respiratory symptoms; abnormal 
CXR 
 266 (46.3) 103 (45.0) 
No respiratory symptoms; normal CXR  16 (2.3) 8 (3.5) 
Respiratory symptoms; abnormal CXR  133 (23.1)  48 (21.0) 
Respiratory symptoms;   normal CXR  160 (27.8) 70 (30.6) 
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4.8.4 Pulmonary NTM Prevalence and Risk Factors  
The estimated prevalence of NTM in pulmonary samples derived from the 2 approaches are 
shown in Table 11. As expected, the lowest prevalence estimate is seen with the most 
conservative model (model 2). The assumption underpinning model 2 is the least realistic and 
provides justification for disregarding this prevalence estimate. The prevalence estimate from 
model 1 in this case is the better option because it uses most of the available data. 
 
Table 11: Estimated overall prevalence of NTM in pulmonary samples in The Gambia 
 
Model 1 
(N=575) 
Model 2 
(N=903) 
NTM prevalence 
estimate 
39.8% (95% CI: 35.8% - 44.0%) 12.8% (95% CI: 8.8% - 18.4%) 
Model 1 = Complete case analysis (analysis of samples that had a complete data for all variables);  model 
2 = Assuming negative data for 328 negative cultures in present (NTM) study 
 
As shown in Table 12, with stratification into the different participant categories, the group 
without respiratory symptoms and normal CXR had the highest proportion of NTM positive 
participants compared to other groups. However, these observed differences were not 
statistically significant (test of difference in proportions, z = -1.1944 p=0.23). This is 
supported by the relatively wide and overlapping 95% CIs.  
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Table 12: Prevalence of NTM across four participant groups in study population n=229 
Participant 
categories 
Total (N) Positive n (%) 95%CI 
 
No respiratory 
symptoms; abnormal 
CXR  
 
266 
 
103 (38.7) 
 
32.8 – 44.7 
No respiratory 
symptoms, normal 
CXR  
 
16 
 
8 (50.0) 
 
24.7 – 75.3 
Respiratory 
symptoms, abnormal 
CXR  
 
133 
 
48 (36.1) 
 
28.0 – 44.9 
Respiratory 
symptoms, normal 
CXR  
 
160 
 
70 (43.8) 
 
36.0 – 51.8 
 
 
Total  
 
575 
 
229 (39.8) 
 
22.6 – 28.3 
95% CI- 95% confidence interval 
 
Table 13 shows the results of univariate logistic regression analysis of predictors/risk factors 
(age group, gender, previous history of TB, region of residence, location, age group, sex and 
location) for the primary study outcome. All age groups were three time as likely to have 
NTM in their sputa as the 15-24 age group, while those who resided in urban areas were 40% 
less likely to be NTM positive. Women were also more likely to have NTM than men. In the 
adjusted model, age, sex and location remained significantly associated with NTM
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Table 13: Investigating the risk factors associated with pulmonary NTM (n=575)  
Risk factor  Unadjusted odds 
ratio (95% CI) 
p-values Adjusted odds 
ratio (95% CI) 
p-values 
Age group      
      15-24  1  1  
      25-34  3.77 (1.32 – 10.79) 0.013 3.2 (1.10 – 9.3) 0.034 
      35-44  3.52 (1.36 – 9.10) 0.009 2.92 (1.11 – 9.10) 0.029 
      45-54  2.90 (1.14 – 7.40) 0.026 2.33 (0.90 – 6.07) 0.081 
      55-64  2.4 (0.94 – 6.13) 0.066 2.41 (0.80 – 5.34) 0.133 
      ≥65  3.36 (1.38 – 8.17) 0.007 2.30 (1.21 – 7.37) 0.017 
Sex      
      Male  1  1  
      Female  1.46 (1.02 - 2.09) 0.039 1.53 (1.02 - 2.09) 0.023 
Location      
      Rural  1  1  
      Urban  0.47 (0.26 - .85) 0.014 0.47 (0.26 - 0.84) 0.012 
Prior TB      
      Yes  1    
      No  1.44 (0.69 – 3.01) 0.330   
Participant categories      
No respiratory symptoms; 
normal CXR 
 1    
No respiratory symptoms; abnormal 
CXR 
 0.76 (0.26 – 2.19) 0.609   
Respiratory symptoms; abnormal CXR  0.67 (0.22 - 1.99) 0.469   
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Respiratory symptoms; normal CXR  0.82 (0.28 – 2.40) 0.715   
4.8.5 Culture Results and Mycobacterium Species Identification and 
Distribution 
A total of 1,145 stored decontaminated sputa (from 903 suspected cases of NTM) were 
inoculated in this study. These yielded 56.0% (641/1,145) of instrument positive AFB 
positive cultures. Mycobacteria specific 16S rRNA gene PCRs amplified 47.3% (303/641) of 
AFB positive cultures as mycobacteria. Sequences from 91.7% (278/303) of samples 
amplified as mycobacteria, were included in the final analysis of which 98.2% (273/278) 
were identified as NTM while 1.8% (5/278) cultures were MTBC. Nearly a tenth (20/273) of 
NTM in the study could not be characterised to species level (see Figure16 below).  
The phylogenetic tree (Figure 17) constructed using the sequences obtained shows 71.1% 
(194/273) of all NTM sequences in this study clustered with M. avium and M. intracellulare 
(M. avium complex) reference strains while 10.0% (26/273) clustered with M. fortuitum and 
M. boenickei (M. fortuitum complex). Other NTM identified - M. nonchromogenicum, M. 
thermoresistible, M. terrae and M. flavescens, were 100% concordant in clustering with 
respective reference strains. However, 20 NTM sequences could not be identified especially 
as they did not cluster with any of the NTM and MTBC reference sequences. The five MTBC 
strains identified in the study also clustered with MTBC reference strains. Table 14 displays 
the mycobacteria species identified, stratified by the different participant groupings in the 
present study
Non-tuberculous Mycobacteria in The Gambia  
 
Page | 98 
    
CHAPTER FOUR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Culture results of non-tuberculous mycobacteria in eligible sputum samples 
at different stages of sample processing
47.3% (303/641) Amplified by mycobacteria specific 16S rRNA gene primers 
 
1,145 stored decontaminated sputa inoculated in MGIT 960 system 
 
415 negative cultures; 
89 instrument +ve, AFB-ve  
56.0% (641/1145) Instrument +ve AFB +ve cultures 
Mycobacteria specific 16S rRNA gene PCRs and agarose gel electrophoresis - 641 cultures 
 
52.7% (338/641)  
not mycobacteria  
98.2% (273/278) NTM 
 
92.7% (278/303) sequences with electropherograms ≥800bp analysed 
 
92.7% (253/273) 
Characterised NTM 
 
7.3% (20/273) Uncharacterised 
NTM 
 
16S rRNA gene sequence analysis on 303 PCR products 
 
8.3% (25/303) <800bp  
- not analysable 
1.2% (5/278) 
           MTBC 
DNA extractions – 641 cultures 
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Figure 17: 
Phylogenetic tree of 
NTM in The Gambia 
based on 16S rRNA 
gene sequence analysis 
of regions A and B of 
mycobacteria gene. 
Red coloured fonts 
represent unknown 
sequences from the 
present study while 
fonts in black colour 
represent NTM and 
MTBC reference 
sequences of ATCC 
strains downloaded 
from GenBank 
Non-tuberculous Mycobacteria in The Gambia  
 
Page | 100 
    
CHAPTER FOUR 
Table 14: The distribution of non-tuberculous mycobacteria species in four participant categories 
Mycobacteria species n (%) No respiratory symptoms; 
abnormal CXR 
No respiratory 
symptoms; normal 
CXR 
Respiratory 
symptoms; 
abnormal CXR 
Respiratory 
symptoms; normal 
CXR 
M. avium complex 194 (71.0) 94 5 41 54 
M. fortuitum 26 (9.5) 12 2 8 4 
M. nonchromogenicum 8 (2.9) 1  3 4 
M. terrae 5 (1.8) 1  2 2 
M. thermoresistible 4 (1.5) 1   3 
M. abscessus 2 (0.7)   1 1 
M. elephantitis 2 (0.7) 2    
M. brumae-like 2 (0.7)    2 
M. flavescens 3(1.1)  1 2  
M. duvalii 1 (0.4)   1  
M. goodii 1 ( 0.4) 1    
M. cosmeticum 1 (0.4)   1  
M. hodleri/isoniacini 1 (0.4) 1    
M. smegmatis 1 (0.4) 1    
M. triviale 1 (0.4)   1  
M. komossense 1 (0.4)    1 
Non-tuberculous Mycobacteria in The Gambia  
 
Page | 101 
    
CHAPTER FOUR 
Uncharacterised NTM 20 (7.3) 7 1 3 9 
Total number of cultures 273 (100) 121 9 63 80 
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4.8.6 Prevalent pulmonary non-tuberculous mycobacteria disease  
The ATS/IDSA diagnostic criteria (see Table 2) was applied to determine the clinical 
relevance of isolated NTM to the 19.2% of participants (44 of 229) that grew NTM in both 
sputa. Only 20.5% (9/44) had clinically relevant pulmonary NTM and all were caused by 
MAC. These nine pateints met the full criteria for pulmonary NTM disease with respiratory 
symtoms, abnormal CXR and same species of NTM found in duplicate sputum samples 
(Figure 18). One patient, 2.3% of 44, had M. fortuitum in both sputa but did not meet clinical 
criteria for NTM disease as this patient had  respiratory symptoms without an abnormal CXR. 
All the clinically relevant pulmonary NTM cases belonged to the participant group with 
respiratory symptoms and CXR abnormalities suggestive of TB (Table 15). Given the 
challenge with obtaining two sputum samples from participants in the parent study, additional 
diagnostic categories of confirmed, probable, suspected and non-pulmonary NTM disease are 
presented in Table 16 below [61, 85]. 
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Figure 18: Outline for clinically relevant NTM in participants with NTM in both sputa. 
 
 
575 Participants  
Complete data set in NTM study 
346 (60.2% of 575) Participants 
Negative for NTM 
9 (20.5% of 44) Participants 
Meet ATS/IDSA criteria 
 Have respiratory 
symptoms and an 
abnormal CXR 
 All MAC 
 
17 (38.6% of 44) Participants  
Do not meet ATS/IDSA criteria  
229 (39.8% of 575) Participants 
Positive for NTM  
185 (80.8% of 229) Participants 
NTM in one sputum   
44 (19.2% of 229) Participants 
NTM in both sputa  
27 (61.4% of 44) Participants 
NTM of same species in both sputa 
17 (38.6% of 44) Participants 
NTM of different species   
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Table 15: The distribution of American Thoracic Society/Infectious Disease Society of 
America defined clinically relevant pulmonary NTM by participant categories 
Participant category Proportion with NTM in 
both samples 
Proportion with NTM 
of same species in both 
samples 
Meets 
ATS/IDSA/ 
number 
No respiratory symptoms; 
abnormal CXR 
19/44 (43.2%) 10/44 (22.7%) 0 
No respiratory symptoms;         
normal CXR 
1/44 (2.3%) 0/44 (0) 0 
Respiratory symptoms; 
abnormal CXR 
13/44 (29.5%) 9/44 (20.6%) 9 
Respiratory symptoms; 
normal CXR 
11/44 (25.0%) 8/44 (18.2%) 0 
Total 44/44 (100%) 27/44 (61.4%) 9/44 (20.5%) 
*American Thoracic Society and Infectious Disease Society of America Diagnostic Criteria for pulmonary 
non-tuberculous mycobacteria. 
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Table 16: Distribution of patients with confirmed, probable, suspected and                 
non-PNTM disease among in study population, n= 575 
Category 
 
 
Parameters Numbers (%) 
Confirmed pulmonary 
NTM disease 
Patient with NTM of same species in both samples, 
respiratory symptoms, abnormal CXR 
 
9 (1.6) 
Probable NTM disease Patient with NTM in one sample, respiratory 
symptoms, abnormal CXR  
 
36 (6.3) 
Suspected NTM disease Patient with different NTM in both sputum samples, 
respiratory symptoms and abnormal chest CXR 
4 (0.6) 
Non-pulmonary NTM 
disease  
Patients with NTM in one or both sputum samples with 
one of the following features: no respiratory symptoms 
nor abnormal CXR or no respiratory symptoms with 
abnormal CXR, respiratory symptoms without 
abnormal CXR 
526 (91.5) 
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4.9 Discussion  
In this chapter, I have described the epidemiology and population biology of NTM isolated 
from pulmonary samples in a representative sample of the Gambian population with respect 
to carriage and clinical disease. The availability of detailed clinical, radiological and 
microbiologic data enabled the discrimination of pulmonary NTM carriage from disease 
through the application of the ATS/IDSA diagnostic criteria. All clinically relevant 
pulmonary NTM were caused by the same NTM species, MAC, which was the most 
prevalent species in carriage. This appears to be the first report on the prevalence of 
pulmonary NTM colonization and disease using a nationally representative sample in a West 
African country. 
This study was executed using the acceptable standards for identification of NTM at every 
step, from cultures to identification by the 16S rRNA gene analysis techniques that I  
optimised for this study [88]. The results are robust and this is further supported by the 
absence of typical NTM contaminants,  a well-documented confounder in other studies where 
for example, subjects rinsed their mouths with M. gordonae-contaminated tap water before 
submitting sputum [2, 27, 65].  
Pulmonary NTM colonisation and disease rates vary globally. In North America and Europe, 
disease and colonisation in the general population range from approximately 1-15/100,000 
persons and 0.1-2/100,000 persons respectively. These rates are largely unknown for many 
countries in sub-Sahara Africa where there is a high burden of active MTBC disease [132, 
138, 139]. In this study, the estimated prevalence of NTM in AFB positive sputum cultures 
that were negative for MTBC [according to the BD MGIT TM TBc Identification (Becton, 
Dickinson and Company, USA) rapid test] and considered suspicious for NTM regardless of 
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clinical relevance, is 39.8%. The prevalence here is higher compared to reports from other 
countries in the sub continent i.e. Nigeria, Ghana, Zambia, Mozambique, Mali and Zimabwe 
[53, 92, 103, 104, 109, 140-142]. However, of all these other studies, only the Zambian and 
Zimbawean ones were similar in design to this Gambian survey of a nationally representative 
population sample. Given that there was missing data for up to 36.2% of the Gambian NTM 
study participants as previously highlighted, NTM prevalence in this study was estimated 
using a complete case analysis approach. Multiple imputation (MI) analysis could have also 
been used to produce an NTM prevalence estimate that utilises all of the data for comparison. 
However, given the complexity of MI techniques, and following statistical advice from my 
institution, this approach was considered beyond the scope of this MPhil project.  
The top three NTM isolated in this study were MAC, M. fortuitum, and M. 
nonchromogenicum, with MAC making up ≥ 70.0% of all NTM put together. This is similar 
to reports by other investigators in North America and European countries [7, 13, 37, 40, 
143], Australia [13, 125, 144], Asia [13, 68, 85, 145, 146] and other countries within sub-
Saharan Africa [9, 13, 53, 102, 103, 110] where MAC are the predominant NTM species in 
pulmonary samples. In my Gambian study, M. fortuitum was second only to MAC while M. 
thermoresistible, M. terrae and M. flavescens were infrequently isolated. As seen in 
Hoefsloot et al [13], rapidly growing NTM (M. fortuitum, M. abscessus) accounted for a tenth 
of all NTM in this study. Contrary to the commonly seen scenario in Europe and Eastern 
Canada [8, 147, 148], there was no M. malmoense and M. xenopi colonisation and/or disease 
in this study population. 
Distinguishing between members of the MAC family (M. intracellulare and M. avium) was 
not complete in this study suggesting some diversity in the regions A and B of the 16S rRNA 
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gene of Gambian MAC strains when compared to those isolated in other regions of the world. 
This hypothesis requires further investigations using molecular techniques of higher 
discriminatory power such as Whole Genomic Sequencing. The issue of diversity for NTM 
most likely extends beyond MAC given that there were no 16S rRNA gene sequences in the 
National Centre for Biotechnology Information (NCBI) data base for 7.3% of NTM in this 
study. This meant that I was unable to identify these NTM down to species level. The clinical 
implications of this group of uncharacterised NTM in The Gambia requires further 
investigation to determine their contribution to pulmonary colonisation and disease.                                                                                                        
Only small proportion of participants, 1.6% had confirmed pulmonary NTM disease based on 
the ATS/IDSA diagnostic criteria.  These diagnostic criteria, despite being widely adopted, 
have not been validated for evaluation of pulmonary NTM disease in The Gambia and sub-
Saharan Africa as a whole. It is possible therefore, that these criteria may be affected by 
geographical, socioeconomic and other predisposing factors that are distributed differently in 
this part of the world. Therefore NTM isolated from participants in the other diagnostic 
categories (probable and suspected PNTM disease) may be clinically relevant. Considering 
that the probability of subsequent clinical disease with one positive NTM culture following 
initial investigation is 4-14% and higher in risk groups, these other categories require further 
investigation [30, 149]. Other guidelines for diagnosing pulmonary NTM diseases include the 
microbiological (microbiological component of ATS/IDSA) diagnostic criteria [7, 61], and 
the British Thoracic Society (BTS) guidelines. The latter were first puplished in the year 
2000 and a draft of the updated version is available online for public consultation [150]. 
Compared to the ATS/IDSA diagnostic criteria, the BTS guidelines are not as widely used 
and reported in literature for differentiating colonisation from disaease.   
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16S rRNA gene sequence analysis detected a few more MTBC cases that were missed in the 
prevalence study.  This is not surprising given that molecular methods used in this study are 
more sensitive than phenotype-based ones used in the prevalence survey. In addition, a few 
studies have reported mutations in the MPT64 antigens (used for confirmation of MTBC 
cultures) that may have resulted in false MPT64 negative results [151, 152].  
Risk factors for pulmonary NTM in sub-Saharan Africa have not been well characterised. 
HIV is a well-recognised driving force for NTM disease for sub-Saharan Africa given its 
association with disseminated NTM disease in those with AIDS [39, 118, 143]. Other 
commonly described risk factors for NTM in industrialised countries include structural lung 
damage (due to chronic obstructive disease, cystic fibrosis, cumulative exposure to tobacco, 
prior tuberculosis) and immunosenescence [39, 40]. Although this study did not explore HIV 
infection as a risk factor for NTM, (because information on HIV status for participants in the 
parent study was not collected) others have shown NTM are increasingly being isolated 
among HIV infected cases [10, 53, 103, 119, 153]. For example, in an evaluation of a cohort 
of 721 persons living with HIV/AIDS in Cote d’Ivoire, the incidence of NTM disaease was 
9.7 times higher among patients with baseline CD4 cell counts less than 100 cells/mm3 
compared to those above 100 cells/mm3 [36]. This finding confirms the significant 
importance of T-cell immunity in the role of NTM and the role of HIV as a major driver of 
NTM infection both in industrialised countries (before the introduction of highly active 
retroviral therapy) and low and middle income countries endemic for TB.  
Rural residence in The Gambia was independently associated with NTM disease infection 
regardless of disease. This may be due to the generally dusty nature of the rural parts of The 
Gambia which together with poor hygiene and nutrition have been shown to increase the risk 
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for NTM disease [3, 154, 155]. Higher risks for environmentally acquired pulmonary 
mycobacterial diseases have also been previously reported among farmers [3] and individuals 
with occupational exposure to dust [154]. Contrary to the above finding, a review from 
Oregon reported pulmonary NTM disease to be more associated with urban regions, 
suggesting a role for urban municipal water supply in NTM transmission and NTM disease 
[156].  As reported elsewhere [2, 7, 40, 157], female sex was positively associated with NTM 
in this study. In the case of gender, reports suggest the epidemiology of NTM disease has 
changed over the last three decades to affect women more frequently than men . The reasons 
for this sex differential are unknown. One hypothesised pathophysiological pathway is the 
lower levels of dehydroepiandrosterone - sulphate (DHEA-S) in women with MAC disease 
compared with control subjects [158]. However, the  study had a small sample size (35 
females) that did not allow for firm conclusions to be drawn.  
There were a few limitations to this study. Since the parent study was primarily designed to 
determine the burden of bacteriological confirmed TB in The Gambia , it could have been 
underpowered to determine the prevalence of pulmonary NTM in both disease and 
colonisation. However, this is probably unlikely given the precision around my estimates.                                                                                                                                  
The unavailability of HIV test results or status in the parent study prevented any investigation 
of HIV as a risk factor for pulmonary NTM colonisation and/or disease. Given HIV 
prevalence is only 1.8% [1.4% - 2.3%] in The Gambia,  the contribution of HIV co-infection 
is most likely minimal [159]. The clinical relevance of NTM in younger children could not be 
ascertained as the parent study only collected specimens from participants aged 15 years or 
more. However, NTM in other parts of the world is predominantly found in older age groups.  
Finally, the methods used for NTM identification could not fully differentiate the MAC and 
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some other species isolated in my study due to limited coverage of the 16S rRNA gene 
database. WGS techniques with proven sensitivity and higher discriminatory power would 
have been more useful for differentiating MAC species and for full identification of the NTM 
in this study. 
In conclusion, this report highlights the contribution of NTM to colonisation and pulmonary 
disease in The Gambia. NTM as commensals in pulmonary samples may confound the 
diagnosis of pulmonary tuberculosis, especially in those with abnormal chest radiographs. 
Given the risk of NTM-related misdiagnosis of PTB, it  may be useful to review the existing 
tuberculosis identification methods for presumptive tuberculosis suspects in The Gambia. 
Additional research and surveillance is therefore required to investigate the full contribution 
of NTM to pulmonary disease, particularly in high risk groups.
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5 Concluding Remarks and Future Pursuits 
Collectively, the findings from my research highlight the contribution of NTM to pulmonary 
colonisation and disease in sub-Saharan Africa.  
As described in the systematic review in chapter 2 [Okoi C, et al. submitted], several studies 
in sub-Saharan Africa have investigated the frequency of pulmonary NTM among 
presumptive  TB cases [53, 104, 108, 110, 140] [Okoi C, et al. submitted], and patients with 
“chronic” pulmonary TB [10, 102, 160]. Although the above studies did not provide adequate 
details regarding the proportion of patients who fulfilled criteria for NTM disease, the 
findings suggest that a substantial proportion of patients in sub-Saharan Africa suspected of 
pulmonary TB or multidrug resistance TB may actually have pulmonary NTM disease, that is 
not detected on routine laboratory analysis.  
As NTM and MTBC show similar clinical manisfestations, evaluation of the role of NTM has 
been well neglected until recently, limiting the available epidemiologic data on pulmonary 
NTM. This further highlights the negative impact of NTM on TB surveillance and control 
system in the sub continent. Thus, understanding the epidemiology of pulmonary NTM 
remains crucial to addressing the burgeoning puplic health challenge [7, 8] noted in TB 
control programs. To this end, a comprehensive multi-country surveillance of NTM is needed 
to better understand the the extent of the burden of pulmonary NTM in carriage and disease 
in sub-Saharan Africa, and to design strategic action plans for effective laboratory diagnostics 
of NTM pulmonary disease and carriage to inform appropriate case management. Finally, 
given the increasing incidence of pulmonary NTM colonisation and disease registered around 
the globe, epidemiological and surveillance data should be obtained through the reporting of 
pulmonary NTM diseases for Public Health decision making.  
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5.1 Further work 
An important follow-up to this work will be to fully characterize the MAC and NTM that 
were not identified in the study using next generation sequencing techniques. This will 
inform a more robust and comprehensive data collection on the epidemiology of pulmonary 
NTM in the Gambia, especially in the area of regional variability within the MAC species.  
Mycobcateria specific 16S rRNA gene PCRs did not amplify 56.3% (324/575) of AFB 
positive cultures that were negative for the MPT64 rapid antigen test in this study. Given 
some other organisms belonging to the genus Nocardia/Rhodococcus have the same acid and 
alcohol fast appearance as NTM and MTBC on microscopy and could have been missed by 
the mycobacteria specific primer PCRs, subjecting this group of samples to standard 16S 
rRNA gene PCR may provide additional information on the pathogen profile of pulmonary 
tuberculosis-like diseases in The Gambia. Pulmonary nocardiosis is often misdiagnosed and 
treated as TB, sometimes with fatal consequences. 
An area of interest around NTM, and one which is under evaluated, is the role of virulence 
factors. Determining this may aid in deciphering the clinical relevance of isolated NTM from 
clinical samples. The species M. kansasii provides a good example: in a previous case series, 
M. kansasii subtype 1 was most strongly  associated with clinical disease while subtypes 3-5 
seemed non-pathogenic. A recent study of the ESX-1 virulence factors of M. tuberculosis 
also evaluated their role in M. kansasii strains and found that M. kansasii sub type 1 had an 
active ESX-1 system which was inactive in M. kansasii sub-type 5 [1, 161]. Assessing such 
virulence factors could be a valuable addition to species identification. 
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Finally, a key issue for diagnosing pulmonary NTM is the recognition of patients at increased 
risk for this disease. With the exception of HIV disease, other factors remain poorly 
understood especially for patients in sub-Saharan Africa.
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